Diagnostic analysis – Mostobd http://mostobd.com/ Wed, 18 May 2022 07:11:28 +0000 en-US hourly 1 https://wordpress.org/?v=5.9 https://mostobd.com/wp-content/uploads/2021/11/favicon-1-120x120.png Diagnostic analysis – Mostobd http://mostobd.com/ 32 32 Artificial Intelligence in Healthcare Market 2022, Trends, Size, Industry Share, Analysis and Forecast to 2028 https://mostobd.com/artificial-intelligence-in-healthcare-market-2022-trends-size-industry-share-analysis-and-forecast-to-2028/ Tue, 17 May 2022 22:02:30 +0000 https://mostobd.com/artificial-intelligence-in-healthcare-market-2022-trends-size-industry-share-analysis-and-forecast-to-2028/ “Health Artificial Intelligence Market” The Healthcare Artificial Intelligence Market is expected to grow at a CAGR of 10.12% to reach US$320 billion by 2028, from US$148 billion in 2020. Healthcare Artificial Intelligence Market Overview: The healthcare artificial intelligence market is expected to grow at a CAGR of 10.12% to reach US$320 billion by 2028, from […]]]>

“Health Artificial Intelligence Market”

The Healthcare Artificial Intelligence Market is expected to grow at a CAGR of 10.12% to reach US$320 billion by 2028, from US$148 billion in 2020.

Healthcare Artificial Intelligence Market Overview:

The healthcare artificial intelligence market is expected to grow at a CAGR of 10.12% to reach US$320 billion by 2028, from US$148 billion in 2020. Artificial intelligence primarily uses algorithms machine learning and deep learning to collect and process data and provide it to the end user. The primary goal of using AI in healthcare is to examine the relationships between prevention techniques and patient outcomes. It is therefore used to analyze a block of data through electronic health records to prevent diseases. One of the major reasons for the growth of this market is the increasing number of chronic diseases and fewer healthcare facilities available. According to the report of the World Economic Forum, “One in three adults in the world suffers from several chronic diseases: cardiovascular diseases alongside diabetes, depression and cancer, or a combination of three, four, even five or six diseases in same time. NCDs represent more than half of the global burden of disease. With the spread of these chronic diseases globally, the healthcare industry has recognized the importance of artificial intelligence in healthcare.

Request sample report @ https://www.statisticalinsights.com/sample-request/7-Healthcare-Artificial-Intelligence-Market

Market segmentation :

The software industry provides many services to the healthcare industry. With the advent of medical software, human errors are minimized in the global medical market. The use of advanced software in the field of health allows clinical experts to assess their practices. Software vendors are gaining huge opportunities in the artificial intelligence (AI) healthcare market. Software development companies are constantly striving to improve the industry and bring innovation.

Presentation of the segments:

The Healthcare Artificial Intelligence Market is segmented as follows:

Global Artificial Intelligence for Healthcare Market, by Product and Services

Software

Material

Services

Global Healthcare Artificial Intelligence Market, By Technology

Machine Learning (ML)

Natural Language Processing (NLP)

Context sensitive processing

Query Method

Global Healthcare Artificial Intelligence Market, By Application

Hospital Workflow Management

Patient data and risk analysis

Medical imaging and diagnostics

drug discovery

Precision medicine

Patient management

Other Apps

Other applications include bioinformatics, wearable devices and virtual assistance. Global Healthcare Artificial Intelligence Market, By End User

Hospitals and diagnostic centers

Pharmaceutical and biopharmaceutical companies

Health Care Payers

The patients

Other end users

Other end users include responsible care organizations, clinical research organizations and managed care organizations Global Healthcare Artificial Intelligence Market, By Geography

North America

WE

Canada

Europe

Germany

France

UK

Italy

Spain

Rest of Europe (RoE)

Asia-Pacific (APAC)

Japan

China

India

Rest of APAC (RoAPAC)

Latin America

Middle East and Africa

A selection of companies mentioned in this report include:

Google

IBM (International Business Machines)

intel company

Medtronic

Microsoft Corporation

Nvidia Corporation

Siemens Healthineers

Arteries

Legend Health

Enlitic

Catalia Health

General view

Phillips

stryker

Shimadzu Recurrence Pharmaceuticals

GE Healthcare

medical remedy

Subtle medical

Netbase Quid

Biosymmetry

sensually

InformAI

Bioclinical

owkin

Binah.AI

Oncora Medical

Full report @ https://www.statisticalinsights.com/main-report/7-Healthcare-Artificial-Intelligence-Market.php

Contents

1. Introduction

1.1. Market definition

1.2. Market ecosystem

1.3. Cash

1.4. Main stakeholders

2. Research methodology

2.1. Research process

2.2. Data collection and validation

2.2.1. Secondary research

2.2.2. Primary research

2.3. Market assessment

2.3.1. Market size estimation

2.3.1.1. An in-depth approach

2.3.1.2. Top-down approach

2.3.1.3. Growth forecasts

2.3.2. Market share analysis

2.4. Study assumptions

2.5. Study limitations

10. Competitive landscape

10.1. Introduction

10.2. Main growth strategies

10.3. Competitive Benchmarking

10.4. Market Share Analysis (2019)

10.4.1. Microsoft Corporation (USA)

10.4.2. GE Healthcare (USA)

10.4.3. IBM Corporation (USA)

11. Company Profiles

11.1. intel company

11.2. IBM Corporation

11.3. NVIDIA Corporation

11.4. Microsoft Corporation

11.5. Alphabet Inc. (Google Inc.)

11.6. GE Healthcare (part of General Electric Company)

11.7. Verint Systems Inc.

11.8. General Vision, Inc.

11.9. Welltok, Inc.

11.10. iCarbonX

12. Appendix

12.1. Quiz

12.2. Personalization available

Carry on…

Relevant posts:

Application Delivery Network Market – By Deployment Type, By End Use, And By Region – Global Industry Opportunity Analysis and Forecast – 2020-2028.

Business Analytics Market – By Software, By End User, By Vertical, And By Region – Global Industry Opportunity Analysis and Forecast – 2021-2028.

About statistical information

The Statistical Insights is one of the largest collections of market research reports from many publishers. We have a team of industry specialists providing unbiased reporting information to best meet the requirements of our clients. We offer a comprehensive collection of competitive market research reports from a number of global leaders across all industry segments. The Statistical Insights research reports are produced by experienced market researchers. The reports will have an in-depth analysis on-

CONTACT US

[email protected]

Phone: + (210) 775-2636 (USA)

+ (91) 853 060 7487

Media Contact
Company Name: Statistical insights
Contact person: John
E-mail: Send an email
Call: (+1) 210-775-2636
Address:Office 709 Kharadi Pride Icon
City: Pune
State: Maharashtra
Country: India
Website: https://www.statisticalinsights.com/


Source link

]]>
Membrane Protein Characterization Service Market 2022-2032 | Country level analysis, current industry size and future outlook with key vendors, drivers and trends https://mostobd.com/membrane-protein-characterization-service-market-2022-2032-country-level-analysis-current-industry-size-and-future-outlook-with-key-vendors-drivers-and-trends/ Tue, 17 May 2022 10:16:40 +0000 https://mostobd.com/membrane-protein-characterization-service-market-2022-2032-country-level-analysis-current-industry-size-and-future-outlook-with-key-vendors-drivers-and-trends/ With a multidisciplinary approach, Fact.MR elaborates an in-depth analysis of the historical, current and future prospects of the global membrane protein characterization services market along with the factors responsible for such growth. Our highly dedicated professionals have provided critical and accurate information associated with each industry and region by conducting extensive primary and secondary research. […]]]>

With a multidisciplinary approach, Fact.MR elaborates an in-depth analysis of the historical, current and future prospects of the global membrane protein characterization services market along with the factors responsible for such growth. Our highly dedicated professionals have provided critical and accurate information associated with each industry and region by conducting extensive primary and secondary research.

We leverage space-age scanning and industrial tools to provide our clients with cutting-edge actionable insights into the membrane protein characterization services market. To enhance readers’ experience, the report begins with a basic overview of the Membrane Protein Characterization Service market and its
classification.

Get an exclusive brochure report Click here:
https://www.factmr.com/connectus/sample?flag=B&rep_id=3410

Membrane Protein Characterization Services Market: Segmentation

The global membrane protein characterization services market is categorized on the basis of membrane protein type, service type, application, end-user, and region.

Based on the Membrane Protein Type Membrane Protein Characterization Services Market, it is segmented as follows:

  • G protein-coupled receptors (GPCRs)
  • Ion channels
  • Membrane receptors

On the basis of service type, the membrane protein characterization services market is segmented as follows:

  • Biophysical characterization
    • Protein Thermal Shift Assay (PTSA)
    • Surface plasmon resonance (SPR)
    • Isothermal titration calorimetry (ITC)
    • Differential Scanning Calorimetry (DSC)
    • Saturation-transfer difference (STD)
    • Biolayer interferometry (BLI) technology
    • Thermal Gravimetric Analysis (TGA)
    • Microscale Thermophoresis (MST)
  • anion or cation exchange chromatography
  • liquid chromatography
  • Gel filtration
  • Transmission electron microscopy
  • Others

Based on Application, the Membrane Protein Characterization Services Market is segmented as follows:

  • Drug discovery and development
  • protein engineering
  • Clinical diagnosis
  • In-vitro diagnostics
  • Vaccine development
  • Antibody development

Based on the End-User Membrane Protein Characterization Services Market, it is segmented as follows:

  • Biotechnology and pharmaceutical industry
  • Research institutes and universities
  • Diagnostic laboratories

Membrane Protein Characterization Service Market: Key Players

Some of the major membrane protein characterization service providers present in the world are Creative Biostructure, Creative-Biolabs, Creative Proteomics, Wyatt Technology Corporation, Creative Diagnostics and others.


To find a Toc report, click here:
https://www.factmr.com/connectus/sample?flag=T&rep_id=3410

Information for each provider includes:

  • Company Profile
  • SWOT analysis
  • Key Market Insights
  • Market share
  • Revenue, Pricing and Gross Margin

What insights does the Membrane Protein Characterization Service market report provide to readers?

  • Market Fragmentation Membrane Protein Characterization Service based on product type, end-use, and region.
  • Comprehensive assessment of upstream raw materials, downstream demand and current market landscape.
  • Collaborations, R&D projects, acquisitions, and product launches of each player in the Membrane Protein Characterization Service market.
  • Various regulations imposed by governments on the consumption of Membrane Protein Characterization Services Market in detail.
  • Impact of modern technologies, such as big data and analytics, artificial intelligence, and social media platforms on the global membrane protein characterization services market.

The report covers the following information and valuation of the Membrane Protein Characterization Service market which is useful for all participants involved in the Membrane Protein Characterization Service market:

  • Data on recently introduced regulations and their impact on key industries and demand for Membrane Protein Characterization Services market
  • Latest industry analysis on the Membrane Protein Characterization Service market with key analysis of market drivers, trends and influencing factors
  • Key Trends Analysis of the Membrane Protein Characterization Services market and changing consumer preferences across key industries.
  • Evolving Membrane Protein Characterization Service Market Demand and Consumption of Various Products
  • Megatrends Underlying Funding by Key Investors in Many Countries
  • New investment opportunities in various technologies and types of products or services
  • Comprehensive Data and Competitive Analysis of Major Membrane Protein Characterization Service Market Players
  • U.S. Membrane Protein Characterization Services Market Sales to Grow at a Steady Rate, Driven by Growing Consumer Confidence and Economic Recovery
  • Membrane Protein Characterization Service Market demand forecast in Europe remains stable as many countries like UK, France and Germany focus on driving growth

Pre-book this report:
https://www.factmr.com/checkout/3410

Questionnaire answered in the Membrane Protein Characterization Service market report includes:

  • How Has the Membrane Protein Characterization Services Market Market Developed?
  • What is the current and future outlook of the global Membrane Protein Characterization Service market on the basis of region?
  • What are the challenges and opportunities for the Membrane Protein Characterization Service market?
  • Why is the Membrane Protein Characterization Services market consumption the highest in the region?
  • In what year should the segment exceed the segment?

For more information on the Fact.MR Trends Report:

https://www.biospace.com/article/demand-for-tricuspid-valve-repair-rising-as-congenital-and-rheumatoid-heart-disease-cases-increase-fact-mr/

About Fact.MR

Market research and consulting agency that makes the difference! That’s why 80% of Fortune 1000 companies trust us to make their most critical decisions. We have offices in the United States and Dublin, while our global headquarters are in Dubai. Although our experienced consultants use the latest technology to extract hard-to-find information, we believe that our USP is the trust our clients place in our expertise. Covering a wide range – from automotive and Industry 4.0 to healthcare and retail, our coverage is extensive, but we ensure that even the most niche categories are analyzed. Contact us with your goals, and we will be a competent research partner.

Contact:
USA Sales Office:
11140 Rockville Pike
Office 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E-mail:
sales@factmr.com

The head office:
Unit number: AU-01-H (AU) gold tower,
Parcel number: JLT-PH1-I3A,
Jumeirah Lakes Tours,
Dubai, United Arab Emirates
Blog URL: https://blog.factmr.com/

The Membrane Protein Characterization Service Market Post 2022-2032 | The country-level analysis, current industry size, and future outlook with key vendors, drivers, and trends appeared first on the latest market reports.


Source link

]]>
Diagnostic Exosome Biomarkers Market to analyze research and development growth with qualitative insights and advanced technologies by 2028 https://mostobd.com/diagnostic-exosome-biomarkers-market-to-analyze-research-and-development-growth-with-qualitative-insights-and-advanced-technologies-by-2028/ Mon, 16 May 2022 12:51:33 +0000 https://mostobd.com/diagnostic-exosome-biomarkers-market-to-analyze-research-and-development-growth-with-qualitative-insights-and-advanced-technologies-by-2028/ Global “Diagnostic Exosome Biomarkers Market » 2022 by Size, Regions, Type and Application, Forecast to 2028 recently presented by SMI, embodies the best results, integrated approaches and latest technologies. The report identifies and interprets each of the market dimensions to assess the logical derivatives that have the potential to fix the growth rate of the […]]]>

Global “Diagnostic Exosome Biomarkers Market » 2022 by Size, Regions, Type and Application, Forecast to 2028 recently presented by SMI, embodies the best results, integrated approaches and latest technologies. The report identifies and interprets each of the market dimensions to assess the logical derivatives that have the potential to fix the growth rate of the global Diagnostic Exosome Biomarkers market. The report provides an in-depth analysis of the status of market development and assessments of various market segments and sub-segments of this industry. The report presents the competitive outlook and growth strategies of the market where the vital regional market demands of the global market are studied.

Acquire Sample Report + All Related Tables & Graphs of Global Diagnostic Exosome Biomarker Market Research Now https://www.stratagemmarketinsights.com/sample/35721

The research report will help market players to develop future business strategies and learn about the global competition. This report provides an overview of various important research industry data and future trends that help identify products and drive revenue growth and profitability. The reports contain an overview and review of the major companies operating in the industry that are considered to be revenue generators for the market.

The key players covered in this report:

101Bio, AMS Biotechnology Limited, BioRegenerative Sciences Inc., Cell Guidance Systems LLC, Codiak BioSciences, Evomic Science LLC, ExoCyte Therapeutics Pte Ltd, Exosome Diagnostics Inc, Exovita biosciences, Immune Therapy Holdings AB, Lonza Group, Norgen Biotek Corp., ReNeuron Group plc

Report overview and scope:

The Diagnostic Exosome Biomarkers market report defines several important characteristics of the market. It will provide the beginnings of this report, describe the needs of this business and the expected results of the research efforts, identify the constraints in the development of a specific solution, the business processes impacted by the project and identify the internal and external entities. The Global Diagnostic Exosome Biomarkers Market report covers the manufacturers, outlines CAGR status, and analyzes its value, potential growth, market competition landscapes, Porter’s Five Forces Analysis, SWOT Analysis, and many development plans over the next few years.

Segmentation by types of products/services:

  • Cancer Institute
  • Hospital
  • diagnostic center
  • Others

Exosome Diagnostic Biomarkers Market Applications:

  • Neurodegenerative disorders
  • Oncology
  • Metabolic disorders
  • Others

Key points that the report recognizes:

✦ Growth rate and market size over the analysis period.
✦ Main market vendors and suppliers.
✦ Comprehensive SWOT analysis of each company.
✦ Detailed PEST analysis by region.
✦ Opportunities and threats faced by the existing vendors in the Diagnostic Exosome Biomarker Market.
✦ Strategic initiatives are taken by leading players.

Revenue and sales estimate:

Historical revenue and sales volume are presented and other data is triangulated with top-down and bottom-up approaches to forecast complete market size and to estimate forecast figures for key regions covered in the report along with types and l end-use classified and well recognized. Industries.

Price analysis:

Price always plays a key role in influencing purchasing decisions. Pricing analysis will help determine how companies value it against other competitors and substitute products. The global diagnostic exosome biomarker market is a research-intensive market driven by high R&D and strong product analysis that helps drive the growth over the analysis period 2022-2028.

Up to 30% off various types of licenses when buying it now (use corporate email id to get higher priority-https://www.stratagemmarketinsights.com/discount/35721

Regional landscape:

State some of the factors which directly affect the market including production strategies, business methods, development platforms and product models. It will also detail the revenues recorded by these given regions. Moreover, the Exosome Diagnostic Biomarkers market report includes specific information on various country-level development plans, potential market restraints, and other restraints to revenue growth. Geographically, the regions covered in the report:

  • North America (US and Canada)
  • Europe (UK, Germany, France and rest of Europe)
  • Asia Pacific (China, Japan, India and Rest of Asia Pacific)
  • Latin America (Brazil, Mexico and rest of Latin America)
  • The Middle East and Africa (GCC and Rest of Middle East and Africa)

Answers to key questions in the report:

☑ What is the growth potential of the Diagnostic Exosome Biomarkers market?
☑ Which product segment will take the lion’s share?
☑ Which regional market will impose itself as a pioneer in the years to come?
☑ Which application segment will experience strong growth?
☑ What growth opportunities might arise in the Diagnostic Exosome Biomarkers industry in the coming years?
☑ What are the most significant challenges that the diagnostic exosome biomarker market may face in the future?

Buy the latest version of this report @ https://www.stratagemmarketinsights.com/cart/35721

Contact us:

Mr Shah
Stratagem Market Overview
Tel: US +1 415 871 0703 / JAPAN +81-50-5539-1737
E-mail: [email protected]

ST


Source link

]]>
In Vitro Diagnostics (IVD) Quality Control Market Analysis by Size, Share, Growth, Application, Segmentation and Forecast to 2029 https://mostobd.com/in-vitro-diagnostics-ivd-quality-control-market-analysis-by-size-share-growth-application-segmentation-and-forecast-to-2029/ Sun, 15 May 2022 12:37:46 +0000 https://mostobd.com/in-vitro-diagnostics-ivd-quality-control-market-analysis-by-size-share-growth-application-segmentation-and-forecast-to-2029/ New Jersey, United States – The In Vitro Diagnostics (IVD) Quality Control Market report includes the upcoming challenges and opportunities in the market. It ensures a strengthened market position and a growing product portfolio by providing all the important details related to the market growth. It reveals some of the key insights and focuses on […]]]>

New Jersey, United States – The In Vitro Diagnostics (IVD) Quality Control Market report includes the upcoming challenges and opportunities in the market. It ensures a strengthened market position and a growing product portfolio by providing all the important details related to the market growth. It reveals some of the key insights and focuses on the impact of the COVID-19 crisis on different sectors of the economy. Identifying key business areas is the single most important factor in improving those areas and generating greater profits. This living market research provides an in-depth understanding of how new product offerings can fit into the market. It acts as the best guide and plays the leading role in almost all phases of the business cycle. It also becomes easy to effectively target customers to easily launch new products. This In Vitro Diagnostics (IVD) Quality Control market indicates that another key focus is to provide manufacturing solutions at all provincial and global levels.

A comprehensive overview of market conditions and various business-related elements is covered in this In Vitro Diagnostics (IVD) Quality Control Market research report. It enables business actors to reach target groups and provides all important details about customers and competitors. Quantitative research methods are used to conduct this market research to provide accurate market data and problem solving. The In Vitro Diagnostics (IVD) Quality Control Market report helps to identify major regions such as Asia-Pacific, North America, Europe, Middle East, Africa and Latin America where new players and merchants can develop their activities. Moreover, it performs in-depth analysis and provides market size, market dynamics, and market share.

Get Sample Full PDF Copy of Report: (Including Full Table of Contents, List of Tables and Figures, Chart) @ https://www.verifiedmarketresearch.com/download-sample/?rid=1329

Also, the market share of each industry over the forecast period is discussed. This market report also provides insights on industry dynamics, market share, growth prospects and challenges. It also conducts market research to determine the growth models, approaches, and techniques used by major players. The most important statistics in the industry trends report provide the perfect reference for businesses. Apart from company profile, capacity, production rate, product value and specifications, the report covers other important parameters.

Key Players Mentioned in the In Vitro Diagnostics (IVD) Quality Control Market Research Report:

Bio-Rad Laboratories, Abbott Laboratories Inc, Thermo Fisher Scientific Inc, Helena Laboratories, Seracare Life Sciences Ortho Clinical Diagnostics, Sun Diagnostics, LLC.

In Vitro Diagnostics (IVD) Quality Control Market Segmentation:

In Vitro Diagnostics Quality Control Market, By Product

• Serum/plasma products
• Whole blood products
• Urine-based products

In Vitro Diagnostics Quality Control Market, By Application

• Immunochemistry
• Clinical chemistry
• Hematology
• Molecular diagnostics
• Coagulation/Hemostasis
• Microbiology

In Vitro Diagnostics Quality Control Market, By End User

• Hospitals
• Clinical laboratories
• Research institutes and universities

Get a discount on the purchase of this report @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=1329

Scope of the In Vitro Diagnostics (IVD) Quality Control Market Report

ATTRIBUTES DETAILS
ESTIMATED YEAR 2022
YEAR OF REFERENCE 2021
FORECAST YEAR 2029
HISTORICAL YEAR 2020
UNITY Value (million USD/billion)
SECTORS COVERED Types, applications, end users, and more.
REPORT COVER Revenue Forecast, Business Ranking, Competitive Landscape, Growth Factors and Trends
BY REGION North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
CUSTOMIZATION SCOPE Free report customization (equivalent to up to 4 analyst business days) with purchase. Added or changed country, region and segment scope.

Answers to key questions in the report:

1. Who are the top five players in the In Vitro Diagnostics (IVD) Quality Control Market?

2. How will the In Vitro Diagnostics (IVD) Quality Control market grow in the next five years?

3. Which products and applications will capture the lion’s share of the in vitro diagnostic (IVD) quality control market?

4. What are the drivers and restraints of the In Vitro Diagnostics (IVD) Quality Control Market?

5. Which regional market will show the strongest growth?

6. What will be the CAGR and market size of the In Vitro Diagnostics (IVD) Quality Control market throughout the forecast period?

For more information or query or customization before buying, visit @ https://www.verifiedmarketresearch.com/product/global-in-vitro-diagnostics-ivd-quality-control-market-size-and-forecast-to-2025/

Visualize the In Vitro Diagnostics (IVD) Quality Control Market Using Verified Market Intelligence:-

Verified Market Intelligence is our BI platform for market narrative storytelling. VMI offers in-depth forecast trends and accurate insights on over 20,000 emerging and niche markets, helping you make critical revenue-impacting decisions for a bright future.

VMI provides a global overview and competitive landscape with respect to region, country and segment, as well as key players in your market. Present your market report and findings with an integrated presentation feature that saves you over 70% of your time and resources for presentations to investors, sales and marketing, R&D and development of products. VMI enables data delivery in Excel and interactive PDF formats with over 15+ key market indicators for your market.

Visualize the In Vitro Diagnostics (IVD) Quality Control Market Using VMI@ https://www.verifiedmarketresearch.com/vmintelligence/

About Us: Verified Market Research®

Verified Market Research® is a leading global research and advisory firm that for over 10 years has provided advanced analytical research solutions, personalized advice and in-depth data analysis to individuals and businesses seeking accurate research, reliable and up to date. data and technical advice. We provide insight into strategic and growth analytics, the data needed to achieve business goals, and help make critical revenue decisions.

Our research studies help our clients make superior data-driven decisions, understand market forecasts, capitalize on future opportunities, and maximize efficiency by working as a partner to deliver accurate and valuable insights. The industries we cover span a wide spectrum, including technology, chemicals, manufacturing, energy, food and beverage, automotive, robotics, packaging, construction, mining and the gas. Etc.

At Verified Market Research, we help in understanding holistic market indicator factors and most current and future market trends. Our analysts, with their deep expertise in data collection and governance, use industry techniques to gather and review data at all stages. They are trained to combine modern data collection techniques, superior research methodology, subject matter expertise and years of collective experience to produce informative and accurate research.

Having served over 5000 clients, we have provided reliable market research services to over 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi. We have co-consulted with some of the world’s leading consulting firms such as McKinsey & Company, Boston Consulting Group, Bain and Company for custom research and consulting projects for companies around the world.

Contact us:

Mr. Edwyne Fernandes

Verified Market Research®

USA: +1 (650)-781-4080
UK: +44 (753)-715-0008
APAC: +61 (488)-85-9400
US toll free: +1 (800)-782-1768

E-mail: sales@verifiedmarketresearch.com

Website:- https://www.verifiedmarketresearch.com/


Source link

]]>
Potential Hearing Diagnostic Devices Market Growth, Share, Demand and Key Players Analysis and Forecast to 2030 – ManufactureLink https://mostobd.com/potential-hearing-diagnostic-devices-market-growth-share-demand-and-key-players-analysis-and-forecast-to-2030-manufacturelink/ Sat, 14 May 2022 14:59:19 +0000 https://mostobd.com/potential-hearing-diagnostic-devices-market-growth-share-demand-and-key-players-analysis-and-forecast-to-2030-manufacturelink/ The Global Hearing Diagnostic Devices Market report emphasizes on detailed understanding of some decisive factors such as size, share, sales, forecast trends, supply, production, demand, industry and CAGR in order to provide a comprehensive perspective of the global market. In addition, the report also highlights challenges hindering market growth and expansion strategies employed by leading […]]]>

The Global Hearing Diagnostic Devices Market report emphasizes on detailed understanding of some decisive factors such as size, share, sales, forecast trends, supply, production, demand, industry and CAGR in order to provide a comprehensive perspective of the global market. In addition, the report also highlights challenges hindering market growth and expansion strategies employed by leading companies in the “Hearing Diagnostic Devices Market”.

Global Hearing Diagnostic Devices Market research report analyzes major players in key regions like North America, South America, Middle East & Africa, Asia & Pacific region. It provides insights and expert analysis on key market trends and consumer behaviors, in addition to an overview of market data and key brands. It also provides all data with easily digestible information to guide every businessman’s future innovation and drive business forward.

Global Hearing Diagnostic Devices Market Segmentation Analysis:

By Top Key Players

Olympus Society
Otopront of Happerdberger
INVENTED
Hedera Biomedical
RION
optomic
Electronic Frying
Natus Medical
Guillaume Demant
Orlvision
Benson Medical Instruments
KARL STORZ
GAES MEDICA
Audidata
Medtronic

By types

Stationary hearing diagnostic devices
Portable hearing diagnostic devices

By apps

Hospital
Clinical
Physical examination center

Click Link to Get Free Sample Copy of Report @ https://crediblemarkets.com/sample-request/hearing-diagnostic-devices-market-483410?utm_source=Amruta&utm_medium=SatPR

Hearing Diagnostic Devices Market, By Geography:

The regional analysis of Hearing Diagnostic Devices Market is studied for regions such as Asia-Pacific, North America, Europe and Rest of the World. North America is one of the major regions in the market owing to numerous cross-industry collaborations between automotive original equipment manufacturers and mobile network operators (MNOs) for seamless internet connectivity inside a car to improve the user experience of connected life. , while driving. The Asia-Pacific region is one of the major players in the market thanks to large enterprises and SMEs in the region that are increasingly adopting hearing diagnostic device solutions.

A few points from the table of contents

Global Hearing Diagnostic Devices Market 2022 by Company, Regions, Type and Application, Forecast to 2030

1 Hearing Aids Introduction and Market Overview

2 Industry Chain Analysis

3 Global Hearing Diagnostic Devices Market, by Type

4 Hearing Diagnostic Devices Market, by Application

5 Global Hearing Diagnostic Devices Consumption, Revenue ($) by Region (2018-2022)

6 Global Hearing Diagnostic Devices Production by Major Regions (2018-2022)

7 Global Hearing Diagnostic Devices Consumption by Regions (2018-2022)

8 Competitive Landscape

9 Global Hearing Diagnostic Devices Market Analysis and Forecast by Type and Application

10 Hearing Aids Market Supply and Demand Forecast by Regions

11 New Project Feasibility Analysis

12 Expert interview file

13 Research finding and conclusion

14 Appendix

Directly Buy This Market Research Report Now @ https://crediblemarkets.com/reports/purchase/hearing-diagnostic-devices-market-483410?license_type=single_user;utm_source=Amruta&utm_medium=SatPR

Reasons to buy this report

  • Qualitative and quantitative market analysis based on segmentation involving both economic and non-economic factors
  • Market value data provision (USD Billion) for each segment and sub-segment
  • Indicates the region and segment expected to grow the fastest and dominate the market
  • Geographical analysis highlighting the consumption of the product/service in the region and indicating the factors affecting the market in each region
  • Competitive landscape that incorporates the market ranking of major players, along with new service/product launches, partnerships, business expansions, and acquisitions over the past five years of profiled companies
  • Comprehensive company profiles including company overview, company information, product benchmarking and SWOT analysis for key market players
  • Current and future industry market outlook with respect to recent developments that involve opportunities and growth drivers along with challenges and restraints of emerging and developed regions
  • Includes in-depth market analysis from various perspectives through Porter’s Five Forces Analysis
  • Provides market insight through the value chain
  • Market dynamics scenario, along with market growth opportunities in the coming years

About Us

Credible Markets is a new era market research company with a firm grip on the pulse of global markets. Credible Markets has become a trusted source for business market research needs in a short period of time. We’ve partnered with leading market intelligence publishers and our report pool coverage spans all key industry verticals and thousands of micro-markets. The massive repository allows our clients to choose from recently released reports from a range of publishers who also provide in-depth analysis by region and country. Moreover, pre-booked research reports are among our best offers.

The collection of market intelligence reports is regularly updated to provide visitors with quick access to the latest market information. We provide round-the-clock support to help you reuse search parameters and benefit from a full range of reserved reports. After all, it’s about helping you make an informed, strategic decision on purchasing the right report that meets all your market research demands.

Contact us

Credible market analyzes

99 Wall Street 2124 New York, NY 10005

E-mail: [email protected]


Source link

]]>
Preeclampsia Diagnostics Market Size, Share, Statistics, Trends, Types, Applications, Analysis and Forecast, Global Industry Research 2027 – ManufactureLink https://mostobd.com/preeclampsia-diagnostics-market-size-share-statistics-trends-types-applications-analysis-and-forecast-global-industry-research-2027-manufacturelink/ Fri, 13 May 2022 06:28:45 +0000 https://mostobd.com/preeclampsia-diagnostics-market-size-share-statistics-trends-types-applications-analysis-and-forecast-global-industry-research-2027-manufacturelink/ The Preeclampsia Diagnostics Market is anticipated to grow at a CAGR of 8.69% and is projected to reach US$XX Billion by 2027, from US$XX Billion in 2020. New York, United States: the Preeclampsia Diagnostics Market The report is written at DECISIVE MARKETS INSIGHTS To provide comprehensive coverage of both clients as well as practical application […]]]>

The Preeclampsia Diagnostics Market is anticipated to grow at a CAGR of 8.69% and is projected to reach US$XX Billion by 2027, from US$XX Billion in 2020.

New York, United States: the Preeclampsia Diagnostics Market The report is written at DECISIVE MARKETS INSIGHTS To provide comprehensive coverage of both clients as well as practical application to market developments. Rising inflation, changing currency value, demand and supply uncertainty, global supply chain disruption, rising unemployment, and emerging tensions between states- United and China are well centered on this report. This Preeclampsia Diagnostics Market The report helps the companies to adopt the tactics to propel their market growth and make the important decision of their crucial investment. crisis to opportunity is well discussed in this report. Government policy on economic stimulus, fiscal stimulus, tax exemption, free trade agreement, regional barrier, skilled labor, land availability and land rule on carbon emissions are well discussed in the report so that it can help companies expand or enter a new region and introduce new products and services.

To avail sample copy of report visit @ https://www.decisivemarketsinsights.com/preeclampsia-diagnostic-market/58646160/request-sample

Preeclampsia Diagnostics Market Segmentation-
By type:
Blood tests Urinalysis
Per application:
Hospitals Specialized clinics Diagnostic centers Other
By key players: Roche PerkinElmer DRG INSTRUMENTS GMBH Thermo Fisher Scientific Diabetomics, Inc. Metabolomic Diagnostics Ltd. Sera Predictions Siemens Healthineers Bayer

This report is broad in concept and content directly from the Preeclampsia Diagnostics market
All data and cases are as current as possible and reflect the current economic and global situation as much as possible. This Preeclampsia Diagnostics Market report considers the economic environment which has significantly helped in making strategic decisions. There is extensive coverage of the omnichannel commerce environment – ​​an evolving practice in which top professionals understand and seamlessly integrate all of their interactions across all commerce channels. This report includes recent technological development and innovation which summarizes the key principle of market growth, consumer behavior as well as relevant examples in the global economy. The global slowdown caused by COVID-19 has led to the contraction of business production and the sharp decline in GDP for all countries. This Preeclampsia Diagnostics Market The report also considers the effect of rising inflation, fluctuations in the price of crude oil, rising unemployment, government fiscal policy, immigration policy, the FTA, the tax exemption, FDI and different environmental policies that help companies make an informed decision for their future activities.

In order to make a pre-order request, please click on the link below:-https://www.decisivemarketsinsights.com/preeclampsia-diagnostic-market/58646160/pre-order-enquiry

This Preeclampsia Diagnostics Market report is a simple approach to creating an innovative solution designed to help the company make an important strategic decision. These reports also help investors and the corporate world understand customer expectations regarding products and services and the level of perception. Also shows the gaps that occur in the market players that we have called supplier gap, are collectively responsible for the customer gap. This Preeclampsia Diagnostics Market The report also identifies the factors responsible for each gap and the influence of technology on each gap. This report also contains information on the extent to which the key players in the respective fields understand the expectations of different customer segments, how much of the business is focused on the relationship with the customers rather than a transaction , and how effectively the company can develop product and service processes. , and how defined are new products and services for customers and employees.

To inquire about the discount, please complete the form by clicking the link below:-https://www.decisivemarketsinsights.com/preeclampsia-diagnostic-market/58646160/request-discount

MAIN NOTES OF THE REPORT:-
• Report has scope for Breakeven Analysis, PESTEL Analysis, SWOT Analysis.
• It contains various charts like bar chart, pie chart, scatter chart, heat map for easy report visualization.
• It shows how the global pandemic has impacted different business houses around the world.

Please click on the link below if you intend to make a direct purchase @:-https://www.decisivemarketsinsights.com/preeclampsia-diagnostic-market/58646160/buy-now

Please contact us and our expert will get back to you within 30 minutes:

Critical market insights
Sunil Kumar
Head of sales
E-mail -[email protected]
Website-https://www.decisivemarketsinsights.com/
United States +18317045538
UK +441256636046
Address:- 26 Broadway, Suite 934, New York, 10004

Social connections:
Twitter @
https://twitter.com/decisivemarket

Linkedin @ https://www.linkedin.com/company/decisive-markets-insights



Source link

]]>
Analysis of the structure of the oncology diagnostics market for the period 2026 – ManufactureLink https://mostobd.com/analysis-of-the-structure-of-the-oncology-diagnostics-market-for-the-period-2026-manufacturelink/ Thu, 12 May 2022 10:23:48 +0000 https://mostobd.com/analysis-of-the-structure-of-the-oncology-diagnostics-market-for-the-period-2026-manufacturelink/ The latest Oncology Diagnostics report estimates the opportunities and current market scenario and provides reports and updates on the corresponding components included in the global Oncology Diagnostics for the forecast period. The report provides detailed analysis of key market dynamics and comprehensive information about the Oncology Diagnostics industry structure. This market study provides an exclusive […]]]>

The latest Oncology Diagnostics report estimates the opportunities and current market scenario and provides reports and updates on the corresponding components included in the global Oncology Diagnostics for the forecast period. The report provides detailed analysis of key market dynamics and comprehensive information about the Oncology Diagnostics industry structure. This market study provides an exclusive view of the expected growth of the Global Oncology Diagnostics Keyword during the forecast period.

To avail sample copy of report visit @ https://decisivemarketsinsights.com/oncology-diagnostics-market/13476862/request-sample

Oncology Diagnostics Market Segmentation-
By type:
Diagnostic imaging Endoscopy Biopsies Immunohistochemistry In situ hybridization Tumor biomarker testing
Per application:
Hospitals Diagnostic imaging centers Research institutes Breast cancer Lung cancer Colorectal cancer Prostate cancer Liver cancer
By key players: Abbott Agilent Technologies Inc. Biomerieux Sa Biocartis Nv Diasorin SPAF Hoffmann-La Roche Ag General Electric Co. Koninklijke Philips NV Siemens Healthcare Gmbh Thermo Fisher Scientific

The Oncology Diagnostics report covers all the key aspects, such as key trends and opportunities for managing the industry dynamics over the forecast period. In addition, it contains various proposals and recommendations on how to effectively manage the current and future challenges of the sector vertically. The document also describes the segments and the size of the market segments, including product type, scope of use, and regional environment. Additionally, it highlights the implications of COVID-19 in this area and explains tactics for effective risk management and high revenue in the coming years.

Key points from the COVID-19 case studies:

The impact of COVID-19 on socio-economic status globally and regionally.
• Supply chain disruptions and fluctuations in demand.
• Market situation before and after the pandemic. Regional Assessment Overview:
• The main regional markets are North America, Europe, Asia-Pacific, South America, the Middle East and Africa.
• The contribution of each region to the overall market growth is studied.
• Considering sales, growth rates and sales in each geographical area.

Another important inclusion in Oncology Diagnostics:

• Market share and sales of each type of product are documented.
• It also provides valuable insights into the production market growth, patterns and annual growth rates in each category over a defined time horizon.

• The estimated growth rate and market share of each type of application during the analysis, as verified statically.
• Listed companies are valued based on factors such as gross margins, market fees, pricing model and production capacity.
• The document reviews key trends and their impact on business to provide a clear picture of the competitive environment.
• A detailed analysis of the industry supply chain is carried out, revealing the major manufacturers, sub-customers and suppliers of raw materials and equipment.
• The report also assesses the investment feasibility of the new project using various procedures, such as Porter’s Five Force evaluation and SWOT analysis.

The latest Oncology Diagnostics report estimates the opportunities and current market scenario and provides reports and updates on the corresponding components included in the global Oncology Diagnostics for the forecast period. The report provides detailed analysis of key market dynamics and comprehensive information about the Oncology Diagnostics industry structure. This market study provides an exclusive view of the expected growth of the Global Oncology Diagnostics Keyword during the forecast period.

The Oncology Diagnostics report covers all the key aspects, such as key trends and opportunities for managing the industry dynamics over the forecast period. In addition, it contains various proposals and recommendations on how to effectively manage the current and future challenges of the sector vertically. The document also describes the segments and the size of the market segments, including product type, scope of use, and regional environment. Additionally, it highlights the implications of COVID-19 in this area and explains tactics for effective risk management and high revenue in the coming years.

Key points from the COVID-19 case sstudies:

The impact of COVID-19 on socio-economic status globally and regionally.

  • Supply chain disruptions and fluctuations in demand.
  • Market situation before and after the pandemic. Regional Assessment Overview:
  • The main regional markets are North America, Europe, Asia-Pacific, South America, Middle East and Africa.
  • The contribution of each region to the overall market growth is studied.
  • Considering sales, growth rates and sales in each geographic area.

Another important inclusion in Oncology Diagnostics:

  • The market share and sales of each type of product are documented.
  • It also provides valuable insights into the production market growth, patterns and annual growth rates in each category over a defined time horizon.
  • • The estimated growth rate and market share of each type of application during the analysis, as verified statically.
  • Listed companies are valued based on factors such as gross margins, market fees, pricing model and production capacity.
  • The document reviews key trends and their impact on business to provide a clear picture of the competitive environment.
  • A detailed analysis of the industry supply chain is carried out, revealing the major manufacturers, sub-customers and suppliers of raw materials and equipment.
  • The report also assesses the investment feasibility of the new project using various procedures, such as Porter’s Five Force evaluation and SWOT analysis.

Some of the most important questions answered in this report:

  • What will be driven by the market growth rate, growth momentum or market acceleration during the forecast period?
  • What are the key factors that change the oncological diagnosis?
  • How big are the oncology diagnoses to come?
  • What would be the size of the next diagnostics in oncology?
  • Which region is expected to have the highest market share in KEYWORDS 1?
  • What trends, challenges, and barriers will affect the development and measurement of Global Keyword 1?
  • What are sales volume, revenue, and price analysis of top manufacturers of Oncology Diagnostics?
  • What are the oncology diagnostics opportunities and threats for traders in the global oncology diagnostics industry?
  • What will be driven by the market growth rate, growth momentum or market acceleration during the forecast period?
  • What are the key factors that change the oncological diagnosis?
  • How big are the oncology diagnoses to come?
  • What would be the size of the next diagnostics in oncology?
  • Which region is expected to have the highest market share in KEYWORDS 1?
  • What trends, challenges, and barriers will affect the development and measurement of Global Keyword 1?
  • What are sales volume, revenue, and price analysis of top manufacturers of Oncology Diagnostics?
  • What are the oncology diagnostics opportunities and threats for traders in the global oncology diagnostics industry?

if you intend to make a Direct purchase please click here

Please contact us and our expert will get back to you within 30 minutes:

Critical market insights
Sunil Kumar
Head of sales
E-mail -[email protected]
Website-https://www.decisivemarketsinsights.com/
United States +18317045538
UK +441256636046
Address:- 26 Broadway, Suite 934, New York, 10004

Social connections:
Twitter-
https://twitter.com/decisivemarket

Linkedin-https://www.linkedin.com/company/decisive-markets-insights



Source link

]]>
Study of 11 common psychiatric disorders shows subsets share same genetic architecture https://mostobd.com/study-of-11-common-psychiatric-disorders-shows-subsets-share-same-genetic-architecture/ Wed, 11 May 2022 15:08:05 +0000 https://mostobd.com/study-of-11-common-psychiatric-disorders-shows-subsets-share-same-genetic-architecture/ More than half of people diagnosed with a psychiatric disorder will experience a second or third in their lifetime. About a third have four or more. This can make treatment difficult and leave patients unlucky and discouraged. But a sweeping new analysis of 11 major psychiatric disorders offers new insight into why comorbidities are the […]]]>

More than half of people diagnosed with a psychiatric disorder will experience a second or third in their lifetime. About a third have four or more.

This can make treatment difficult and leave patients unlucky and discouraged.

But a sweeping new analysis of 11 major psychiatric disorders offers new insight into why comorbidities are the norm, rather than the exception, in mental illness. The study, published this week in the journal Natural genetics, found that while there is no underlying risk gene or set of genes for each, subsets of disorders – including bipolar disorder and schizophrenia; anorexia nervosa and obsessive-compulsive disorder; and major depression and anxiety – share a common genetic architecture.

“Our results confirm that high comorbidity in some disorders partly reflects overlapping genetic risk pathways,” said lead author Andrew Grotzinger, assistant professor in the Department of Psychology and Neuroscience.

The discovery could ultimately open the door to treatments that address multiple psychiatric disorders at once and help reshape the way diagnoses are given, he said.

“If you had a cold, you wouldn’t want to be diagnosed with a cough disorder, a sneezing disorder, and a sore joint disorder,” Grotzinger said. “This study is a stepping stone towards creating a diagnostic manual that better maps what is really going on biologically.”

In search of genetic models

For the study, Grotzinger and colleagues from the University of Texas at Austin, Vrije Universiteit Amsterdam and other collaborating institutions analyzed publicly available genome-wide association data (GWAS) from hundreds of thousands of people who have submitted genetic material to large-scale datasets, such as the UK Biobank and the Psychiatric Genomics Consortium.

They looked at the genes associated with 11 disorders, including: schizophrenia, bipolar disorder, major depressive disorder, anxiety disorder, anorexia nervosa, obsessive-compulsive disorder, Tourette’s syndrome, post- trauma, problematic alcohol use, ADHD and autism. Additionally, they looked at data collected through wearable motion tracking devices and survey data documenting physical and behavioral traits.

Next, they applied new statistical genetic methods to identify common patterns across the disorders.

They found that 70% of the genetic signal associated with schizophrenia is also associated with bipolar disorder. This finding was surprising because, according to current diagnostic guidelines, clinicians generally do not diagnose an individual with both.

They also found that anorexia nervosa and obsessive-compulsive disorder have a strong and shared genetic architecture and that people with a genetic predisposition to have a smaller body type or a low BMI (body mass index) also have tend to have a genetic predisposition to these disorders. .

Not surprisingly, as the two diagnoses often go hand in hand, the study found significant genetic overlap between anxiety disorder and major depressive disorder.

When analyzing the accelerometer data, the researchers found that disorders that tend to cluster also tend to share genes that influence how and when we move during the day.

For example, people with internalizing disorders, such as anxiety and depression, tend to have a genetic architecture associated with low movement throughout the day. Compulsive disorders (OCD, anorexia) tend to be correlated with genes associated with greater movement throughout the day, and psychotic disorders (schizophrenia and bipolar disorder) tend to be genetically correlated with excessive movement during the day. early morning.

“When you think about it, it makes sense,” Grotzinger said, noting that depressed people often present as tired or low-energy while those with compulsive disorders may have difficulty staying still.

Therapy for multiple disorders

In total, the study identifies 152 genetic variants shared by several disorders, including those already known to influence certain types of brain cells.

For example, genetic variants that influence brain excitatory and GABAergic neurons – which are involved in critical signaling pathways in the brain – appear to strongly underlie the genetic signal shared by schizophrenia and bipolar disorder.

Although much work remains to be done to determine exactly what the identified genes do, Grotzinger sees the research as a first step toward developing therapies that can treat multiple disorders with a single treatment.

“People today are more likely to be prescribed multiple medications to treat multiple diagnoses, and in some cases these medications can have side effects,” he said. “By identifying what is shared across these issues, we can hopefully find ways to target them in a different way that doesn’t require four separate pills or four separate psychotherapy interventions.”

In the meantime, simply understanding the genetics underlying their disorders may reassure some.

“It’s important for people to know that they haven’t just had a terrible roll of the dice in life – that they’re not dealing with several different issues, but rather a set of risk factors that overwhelm them. all.”


Source link

]]>
Global Procalcitonin Testing (In Vitro Diagnostics) Market Analysis and Forecast, 2015-2021 and 2021-2030 https://mostobd.com/global-procalcitonin-testing-in-vitro-diagnostics-market-analysis-and-forecast-2015-2021-and-2021-2030/ Tue, 10 May 2022 17:35:00 +0000 https://mostobd.com/global-procalcitonin-testing-in-vitro-diagnostics-market-analysis-and-forecast-2015-2021-and-2021-2030/ DUBLIN, May 10, 2022–(BUSINESS WIRE)–The “Procalcitonin Testing (In Vitro Diagnostics) – Global Market Analysis and Forecast Model” report has been added to from ResearchAndMarkets.com offer. Procalcitonin Testing (In Vitro Diagnostics) – Global Market Analysis and Forecasting Model (COVID-19 Market Impact) is designed to visualize quantitative market trends in the therapeutic area of ​​In Vitro Diagnostics. […]]]>

DUBLIN, May 10, 2022–(BUSINESS WIRE)–The “Procalcitonin Testing (In Vitro Diagnostics) – Global Market Analysis and Forecast Model” report has been added to from ResearchAndMarkets.com offer.

Procalcitonin Testing (In Vitro Diagnostics) – Global Market Analysis and Forecasting Model (COVID-19 Market Impact) is designed to visualize quantitative market trends in the therapeutic area of ​​In Vitro Diagnostics.

Sepsis is a life-threatening condition characterized by organ dysfunction caused by a patient’s dysregulated response to infection. Sepsis is related to but distinct from sepsis, which is the spread of bacterial infection through the bloodstream; sepsis is the dysregulated host response to this infection.

Advanced sepsis is associated with a high mortality rate (20-30%) with contributing factors such as late diagnosis, inappropriate clinical management and suboptimal quality of care. The age distribution of people with sepsis is largely biphasic, primarily affecting newborns (and their mothers) and the elderly; older patients with sepsis tend to have a wide range of comorbidities. Sepsis can rapidly progress to a condition known as septic shock, where profound circulatory, cellular, and metabolic abnormalities present a higher risk of mortality.

The dosage of procalcitonin makes it possible to distinguish a bacterial infection from a viral infection and to monitor the effectiveness of an antibiotic treatment. However, these tests are not used exclusively for patients with sepsis. Procalcitonin can be used in patients with lower respiratory tract infections (LRTIs), bacterial pneumonia, or to monitor patients requiring mechanical ventilation for potential infection.

Respiratory infections, including various pneumonias, are the most common cause of sepsis, and ventilated patients may also be sepsis in addition to other comorbidities.

Due to the non-mutually exclusive nature of these conditions, sepsis was chosen as the primary disease state and indication for this market model. All other indications requiring procalcitonin testing are intended to be covered under “Other Indications” on each country tab in this template.

Scope

  • CMO leaders who need to have an in-depth understanding of the Procalcitonin Testing market to make strategic planning and investment decisions.

  • Procurement and procurement managers who need to understand the critical elements of the supply base in order to make decisions regarding vendor selection and management.

  • Private equity investors who need a deeper understanding of the market to identify and assess potential investment targets.

Reasons to buy

  • To understand the impact of COVID-19 on the Procalcitonin Testing Market.

  • Develop and design your licensing and out-licensing strategies through a review of pipeline products and technologies, and identifying the companies with the strongest pipeline.

  • Develop business strategies by understanding the trends shaping and driving the Procalcitonin Testing market.

  • Generate revenue by understanding the key trends, innovative products and technologies, market segments, and companies that are likely to impact the Procalcitonin Testing Market in the future.

  • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the company’s share among market leaders.

  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.

  • Track device sales in the global and country procalcitonin testing market from 2015 to 2030.

  • Organize your sales and marketing efforts by identifying the categories and market segments that present the maximum opportunities for consolidations, investments and strategic partnerships.

Companies covered

  • Abbott Laboratories

  • Danaher Corp.

  • Backman Coulter

  • F. Hoffmann-La Roche SA

  • DiaSorin SpA, bioMérieux SA

  • Siemens Healthineers SA

  • Ortho-clinical diagnosis and

  • Diazyme Laboratories Inc.

For more information about this report visit https://www.researchandmarkets.com/r/1yze55

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220510006291/en/

contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Officer
press@researchandmarkets.com

For EST business hours, call 1-917-300-0470
For US/CAN call toll free 1-800-526-8630
For GMT office hours call +353-1-416-8900


Source link

]]>
CASTLE BIOSCIENCES INC Management report and analysis of the financial situation and operating results. (Form 10-Q) https://mostobd.com/castle-biosciences-inc-management-report-and-analysis-of-the-financial-situation-and-operating-results-form-10-q/ Mon, 09 May 2022 21:12:08 +0000 https://mostobd.com/castle-biosciences-inc-management-report-and-analysis-of-the-financial-situation-and-operating-results-form-10-q/ You should read the following discussion and analysis of financial condition and results of operations together with our unaudited condensed consolidated financial statements and the related notes and other financial information included in this Quarterly Report on Form 10-Q and our audited financial statements and notes thereto as of and for the years ended December […]]]>
You should read the following discussion and analysis of financial condition and
results of operations together with our unaudited condensed consolidated
financial statements and the related notes and other financial information
included in this Quarterly Report on Form 10-Q and our audited financial
statements and notes thereto as of and for the years ended December 31, 2021 and
2020 and the related Management's Discussion and Analysis of Financial Condition
and Results of Operations, including the section entitled "Critical Accounting
Estimates," included in our Annual Report on Form 10-K for the year ended
December 31, 2021, filed with the Securities and Exchange Commission (the "SEC")
on February 28, 2022. Unless the context requires otherwise, references in this
Quarterly Report on Form 10-Q to "we," "us" and "our" refer to Castle
Biosciences, Inc.

Forward-looking statements


The information in this discussion contains forward-looking statements and
information within the meaning of Section 27A of the Securities Act of 1933, as
amended (the "Securities Act"), and Section 21E of the Securities Exchange Act
of 1934, as amended (the "Exchange Act"), which are subject to the "safe harbor"
created by those sections. These forward-looking statements include, but are not
limited to, statements concerning the impacts of COVID-19 on our business, our
strategy, future operations, future financial position, future revenues,
projected costs, prospects and plans and objectives of management. The words
"anticipate," "believe," "estimate," "expect," "potential," "may," "plan,"
"will," "would" or the negative or plural of these terms or other similar
expressions are intended to identify forward-looking statements, although not
all forward-looking statements contain these identifying words. We may not
actually achieve the plans, intentions or expectations disclosed in our
forward-looking statements and you should not place undue reliance on our
forward-looking statements. Actual results or events could differ materially
from the plans, intentions or expectations disclosed in the forward-looking
statements that we make. These forward-looking statements involve risks and
uncertainties that could cause our actual results to differ materially from
those in the forward-looking statements, including, without limitation, the
risks set forth in Part II, Item 1A., "Risk Factors" in this Quarterly Report on
Form 10-Q and in our other filings with the SEC. The forward-looking statements
are applicable only as of the date on which they are made, and we do not assume
any obligation to update any forward-looking statements, except as may be
required by law.

Insight


Castle Biosciences is improving health through innovative tests that guide
patient care. For the diseases that our portfolio of tests cover, we believe the
traditional approach to developing a treatment plan for cancers and other
diseases using clinical and pathology factors alone is inadequate and can be
improved by incorporating the personalized information our diagnostic and
prognostic tests provide.

We currently market five proprietary multi-analyte assays with algorithmic
analysis ("MAAAs") designed to answer clinical questions in dermatologic
cancers, uveal melanoma ("UM") (a rare cancer of the eye) and Barrett's
esophagus ("BE"). We also have a pharmacogenomic test to guide optimal drug
treatment for patients suffering from depression, anxiety and other mental
health conditions following our acquisition of AltheaDx, Inc. ("AltheaDx") in
April 2022, as discussed below. Our revenue is primarily generated by our
DecisionDx®-Melanoma risk stratification test for cutaneous melanoma, a deadly
skin cancer, and our DecisionDx®-UM risk stratification test for UM.

The foundation of our business is our dermatologic cancer franchise, and our
lead product is DecisionDx-Melanoma, a proprietary risk stratification gene
expression profile ("GEP") test that predicts the risk of metastasis or
recurrence for patients diagnosed with invasive cutaneous melanoma. In the
management of melanoma, as with nearly all diseases, treatment plans are
directed by patient risk-stratification. This test has two distinct,
complementary clinically actionable uses. The first revolves around predicting
the likelihood of having a sentinel lymph node ("SLN") negative biopsy result so
that physicians and patients can discuss the risk and benefit of undergoing the
SLN biopsy ("SLNB") surgical procedure. The second use is to inform the
appropriate treatment plan during the initial five years post-diagnosis,
regardless of the decision to undergo or avoid invasive SLNB surgery. In a
typical year, we estimate approximately 130,000 patients are diagnosed with
invasive cutaneous melanoma in the United States. We launched
DecisionDx-Melanoma in May 2013. Based on the substantial clinical evidence that
we have developed, we have received Medicare coverage for DecisionDx-Melanoma,
which represents approximately 50% of the addressable patient population for
this test.

On August 31, 2020, we commercially launched our cutaneous squamous cell
carcinoma ("SCC") proprietary GEP test, DecisionDx®­SCC, for use in patients
with one or more risk factors (also referred to as "high-risk" SCC). On November
2, 2020, we commercially launched our proprietary GEP test for
difficult-to-diagnose melanocytic lesions, DecisionDx® DiffDx™-Melanoma, for use
in patients with a melanocytic lesion and uncertainty related to the malignancy
of the lesion. We believe that these two additional skin cancer tests address
areas of high clinical need in dermatological cancer and, together, represent an
estimated addressable population of approximately 500,000 patients in the United
States.

                                       16

————————————————– ——————————

Contents


We further expanded our commercially available dermatologic portfolio in May
2021 when we acquired Myriad myPath, LLC (the "Myriad myPath Laboratory") from
Myriad Genetics, Inc. for a cash purchase price of $32.5 million. myPath
Melanoma is a clinically validated GEP test that addresses the same unmet
clinical need as our DecisionDx DiffDx-Melanoma test. Today, we offer both our
myPath Melanoma test and our DecisionDx DiffDx-Melanoma test under an offering
that we refer to as our comprehensive diagnostic offering ("CDO") of molecular
testing solutions. By offering both of these tests in a single offering, we
believe we have demonstrated the ability to improve the test result performance
for patients with difficult-to-diagnose melanocytic lesions.

In 2021, we announced the launch of our innovative pipeline initiative to
develop a genomic test aimed at predicting response to systemic therapy in
patients with moderate to severe psoriasis, atopic dermatitis and related
inflammatory skin conditions. In the United States alone, there are
approximately 18 million patients diagnosed with psoriasis and atopic
dermatitis. Approximately 450,000 of these patients annually are eligible for
systemic therapies. If successful, this inflammatory skin disease pipeline test
has the potential to add approximately $1.9 billion to our current estimated
U.S. total addressable market ("TAM"). In 2021, we initiated a 4,800 patient,
prospective, multi-center clinical study to develop and validate this pipeline
test and have 52 committed sites and approximately 146 patients enrolled. Based
upon our current development and validation timelines, we expect to have initial
validation and development data in 2023 and to commercialize this pipeline test
by the end of 2025.

In addition to our dermatologic franchise, we also market a test for patients
diagnosed with UM. DecisionDx®-UM is a proprietary, risk stratification GEP test
that predicts the risk of metastasis for patients with UM. We believe
DecisionDx-UM is the standard of care in the management of newly diagnosed UM in
the majority of ocular oncology practices in the United States. We launched
DecisionDx-UM in January 2010. Based on the substantial clinical evidence that
we have developed, we have received Medicare coverage for DecisionDx-UM, which
represents approximately 50% of the addressable patient population for this
test.

In December 2021, we extended our commercial portfolio of proprietary tests into
the gastroenterology market through our acquisition of Cernostics, Inc.
("Cernostics") and the TissueCypher® platform. The TissueCypher platform focuses
on unlocking, in the case of the initial test for use in patients with BE, the
importance of the location of the expression of proteins or lack thereof within
the morphology of the disease (also known as spatialomics). This "spatialomic"
information is then interpreted using artificial intelligence approaches to
predict the likelihood of progression to high-grade dysplasia and/or esophageal
cancer in patients with non-dysplastic, indefinite or low-grade dysplasia BE. We
believe the addition of expertise in the spatialomics area positions us for
continued growth and success in the diagnostics space, complementing our
first-to-market dermatologic franchise and our proprietary test for UM.

On April 26, 2022, we completed our acquisition of AltheaDx, a commercial-stage
molecular diagnostics company specializing in the field of pharmacogenomics
("PGx") testing services that are focused on mental health, and the provider of
IDgenetix, a PGx test for mental health conditions. At closing, $65.0 million in
initial consideration was payable by us to AltheaDx security holders, which
consisted of $32.5 million in cash, subject to adjustments for cash, debt,
transaction expenses and working capital, and $32.5 million in shares of our
common stock. Further, up to an additional $75.0 million in cash and common
stock may become payable in connection with the achievement of certain
milestones based on 2022, 2023 and 2024 performance and expanded Medicare
coverage for the IDgenetix test. This acquisition enables us to offer a testing
solution that we believe has the potential to accelerate our impact on patient
care in an area of high unmet clinical need, significantly expand our in-market
estimated U.S. TAM by approximately $5.0 billion and offer incremental value to
patients and clinicians over the standard of care trial-and-error approach. A
randomized controlled trial showed that patients diagnosed with depression, who
were assessed with the IDgenetix test, showed a 2.5 times improvement in
remission rates compared to those who did not have their genes tested.

The number of test reports we generate is a key indicator that we use to assess
our business. A test report is generated when we receive a sample in our
laboratory, and then the relevant test information is entered into our
Laboratory Information Management System, the expression of the biomarkers is
measured, then a proprietary algorithmic analysis of the combined biomarkers is
performed to generate a report providing the results of that analysis, which is
sent to the clinician who ordered the test.

                                       17

————————————————– ——————————

Contents


The number of GEP test reports delivered by us during the three months ended
March 31, 2022 and 2021 and for the year ended December 31, 2021 are presented
in the table below:

                                                              Proprietary Dermatologic GEP Tests
                              DecisionDx-                                                                                                                             TissueCypher Barrett's
                                Melanoma                  DecisionDx-SCC                  CDO(1)                Dermatologic Total            DecisionDx-UM                Esophagus(2)              Grand Total
Q1 2022                           6,023                        1,142                          950                      8,115                         456                            56                 8,627

Q1 2021                           4,060                          527                          218                      4,805                         337                             -                 5,142
Q2 2021                           5,128                          784                          627                      6,539                         468                             -                 7,007
Q3 2021                           5,505                          934                          913                      7,352                         375                             -                 7,727
Q4 2021                           5,635                        1,265                          904                      7,804                         438                            27                 8,269
For year ended December
31, 2021                         20,328                        3,510                        2,662                     26,500                       1,618                            27                28,145



(1)Includes DecisionDx DiffDx-Melanoma, which we launched commercially on
November 2, 2020and myPath Melanoma, which we started offering following our acquisition of the Myriad myPath laboratory on May 28, 2021. We offer both myPath Melanoma and DecisionDx DiffDx-Melanoma as part of our CDO.

(2) We started offering the TissueCypher Barrett Esophagus Test on December 3, 2021following the completion of our acquisition of Cernostic.


For the three months ended March 31, 2022, our dermatologic test report volume
increased by 68.9% compared to the prior period in 2021, largely driven by
continued growth from our DecisionDx-Melanoma test. For a discussion of how we
recognize revenue derived from our tests, refer to "Net Revenues" under
"Components of Results of Operations" below.

The principal focus of our current commercial efforts is to educate clinicians
and pathologists on the value of our molecular diagnostic testing products
through our direct sales force in the United States. During the first half of
2021, we expanded our dermatologic commercial team, bringing our dermatologic
sales force to the mid-60s. In connection with our acquisition of Cernostics in
December 2021, we hired an initial commercial team of approximately 14 outside
sales territories, along with commensurate internal sales associates and medical
science liaisons, to support our launch of the TissueCypher Barrett's Esophagus
test. This dedicated team focuses on gastroenterology specialists that diagnose
and manage patients with BE. Similar to our dermatology commercial team, we will
continue to assess market response and determine what an appropriate commercial
expansion will look like. Based on our initial market research, as well as
initial provider response, we expect to add approximately 10-15 additional
outside sales territories sometime in the third quarter, ending the year with
approximately 25-30 outside sales territories. AltheaDx, which we acquired in
late April 2022, had a commercial team covering approximately 20 outside sales
territories, all of whom have continued with Castle following the transaction.

We continue to see new clinicians order our dermatologic tests for the first
time. For the three months ended March 31, 2022, we saw approximately 592 new
ordering clinicians for our dermatologic tests compared to 410 during the same
period of 2021. Total ordering clinicians for our dermatologic tests were
approximately 3,629 and 2,456 for the three months ended March 31, 2022 and
2021, respectively.

For more information about the metrics we disclose, see “Information About Certain Metrics” below.


In developing our DecisionDx-SCC and DecisionDx DiffDx-Melanoma tests, we
believed that in addition to addressing significant unmet clinical needs, we
would see strategic opportunities for leverage, as many of the clinicians
currently ordering DecisionDx-Melanoma would likely be the same clinicians who
would find value in these other dermatologic GEP tests. For example, we found
that for the three months ended March 31, 2022, approximately 56% of all
clinicians ordering DecisionDx-SCC had also ordered our DecisionDx-Melanoma test
during that same period.

We bill third-party payors and patients for the tests we perform. The majority
of our revenue collections is paid by third-party insurers, including Medicare.
We have received local coverage determinations ("LCDs"), which provide coverage
for our DecisionDx-Melanoma, myPath Melanoma, DecisionDx-UM and IDgenetix tests
that meet certain criteria for Medicare and Medicare Advantage beneficiaries,
representing approximately 60 million covered lives. In 2022, DecisionDx-UM
received coverage from United Healthcare that represents approximately 43
million covered lives. A ''covered life'' means a subscriber, or a dependent of
a subscriber, who is insured under an insurance carrier's policy. The
TissueCypher Barret's Esophagus test is paid by Medicare at the rate published
on Medicare's Clinical Laboratory Fee Schedule ("CLFS") for the test. Effective
March

                                       18

————————————————– ——————————

Contents

On February 24, 2022, we received ADLT status for our TissueCypher test, as discussed in more detail below. ADLT status exempts TissueCypher from what’s called the “14-day rule,” which simplifies the billing process for Medicare patients.


Palmetto GBA MolDX ("Palmetto"), the Medicare Administrative Contractor ("MAC")
responsible for administering MolDX, the program that assesses molecular
diagnostic technologies, issued a final expanded LCD for DecisionDx-Melanoma,
effective November 22, 2020. With this expanded LCD and the accompanying billing
and coding articles, we estimate that a significant majority of the
DecisionDx-Melanoma tests performed for Medicare patients will meet the coverage
criteria. Noridian Healthcare Solutions, LLC ("Noridian"), the MAC responsible
for administering claims for laboratory services performed in Arizona, has
adopted the same coverage policy as Palmetto and also issued an expanded final
LCD for DecisionDx-Melanoma, effective December 6, 2020.

Separately, Palmetto issued a final LCD for DecisionDx-UM, which became
effective in July 2017, and Noridian issued a similar LCD that became effective
in September 2017. The Noridian LCD provides for coverage to determine
metastatic risk in connection with the management of a patient's newly diagnosed
UM and to guide surveillance and referral to medical oncology for those
patients.

On May 17, 2019, Centers for Medicare & Medicaid Services ("CMS") determined
that DecisionDx-UM meets the criteria for "existing advanced diagnostic
laboratory test" status, also referred to as "existing ADLT" status. For 2020,
our rate was set by Noridian, our local MAC, but effective in 2021 our rate is
set annually based upon the median private payor rate for the first half of the
second preceding calendar year. Our rate for 2021 was $7,776 and will remain at
$7,776 for 2022, in each case based on the calculation of the median private
payor rate.

Also, on May 17, 2019, CMS determined that DecisionDx-Melanoma meets the
criteria for "new ADLT" status. Accordingly, from July 1, 2019, through March
31, 2020, the Medicare reimbursement rate was equal to the initial list price of
$7,193. From April 1, 2020, through December 31, 2021, the rate was also $7,193,
which was calculated based upon the median private payor rate for
DecisionDx-Melanoma from July 1, 2019 to November 30, 2019. CMS has informed us
that the rate for 2022 will continue to be $7,193, based on the median private
payor rate.

myPath Melanoma is currently covered under a MolDX LCD policy through Noridian,
which oversees laboratories in both Utah and Arizona. Noridian issued an LCD
that became effective in June 2019. On September 6, 2019, myPath Melanoma was
approved as a new ADLT. The rate for 2022 will be $1,950.

Beginning in 2023, the rates for DecisionDx-Melanoma, DecisionDx-UM, and myPath
Melanoma tests will be set annually based upon the median private payor rate for
the first half of the second preceding calendar year. For example, the rate for
2023 will be set using median private payor rate data from January 1, 2021 to
June 30, 2021.

TissueCypher is performed in our Pittsburgh, Pennsylvania laboratory and falls
under the Medicare jurisdiction that is managed by Novitas Solutions
("Novitas"). Novitas previously reviewed TissueCypher and we are receiving
payments for claims according to the CLFS. For 2022, CMS published in its CLFS a
payment amount of $2,513 for the test. On March 24, 2022, CMS determined that
TissueCypher meets the criteria for "new ADLT" status. From April 1, 2022
through December 31, 2022, CMS has set the initial period rate equal to the
original list price of $2,350, subject to the possible recoupment provision
described below. Effective January 1, 2023, the rate will be based on the median
private payer rates received between April 1, 2022 and August 31, 2022. Note
that for TissueCypher tests reported for April 1, 2022 through December 31,
2022, CMS has the right to recoup the difference between the actual list and
130% of the weighted median if the original list price was greater than 130% of
the weighted median of private payor rates.

IDgenetix is currently covered under a MolDX LCD policy and an accompanying
billing and coding article through Noridian, which oversees laboratories in
California. The Medicare coverage includes depression and was recently expanded
for the following seven additional mental health conditions beyond major
depressive disorder: schizophrenia, bipolar disorder, anxiety disorders, panic
disorder, obsessive-compulsive personality disorder, post-traumatic stress
disorder and attention deficit hyperactivity disorder. The IDgenetix multi-gene
panel is currently reimbursed by Medicare at approximately $1,500.

In the second quarter of 2020, we submitted our technical assessment dossier for
DecisionDx-SCC to Palmetto and Noridian. The dossier was accepted as complete in
the third quarter of 2020. In early 2021, we submitted our technical assessment
dossier for DecisionDx DiffDx-Melanoma. The dossier was accepted as complete in
the first quarter of 2021. We are unable to predict when draft LCDs for
DecisionDx-SCC and DecisionDx DiffDx-Melanoma will be posted and there is no
assurance that any draft or final LCD will match our expectations, be posted in
a timeframe consistent with our historical experience or will be posted at all.

In the second quarter of 2021, Palmetto and the other MACs that participate in
the MolDX program each released a revised draft LCD for DecisionDx-Melanoma. The
draft LCD includes commentary about two publications regarding the clinical
utility of GEP tests and includes an assessment stating that the new data is not
sufficient to change the coverage criteria. There was an open public comment
period, and we submitted comments in support of Medicare coverage. The comment
period ended on

                                       19

————————————————– ——————————

Contents


August 8, 2021. Potential outcomes following the public comment period include
the posting of a final LCD consistent with the draft LCD, issuing a final LCD
with coverage changes or not issuing a final LCD at all. We are unable to
predict the ultimate outcome of this matter.

Since becoming a public company, we have financed our operations with the
revenue generated from the sale of our products, proceeds from our initial
public offering of our common stock (our "IPO") that closed in July 2019,
follow-on public offerings of common stock in June 2020 and December 2020 and
bank debt, which has since been repaid in full. We believe that our existing
cash and cash equivalents and anticipated cash generated from sales of our
products will be sufficient to fund our operations for the next 12 months and
into the foreseeable future. However, we have based these estimates on
assumptions which may prove to be wrong and could result in us depleting our
capital resources sooner than expected.

Our net (loss) income may fluctuate significantly from period to period,
depending on the timing of our planned development activities, the growth of our
sales and marketing activities and the timing of revenue recognition under
Accounting Standards Codification Topic 606, Revenue from Contracts with
Customers ("ASC 606"). We expect our expenses will increase substantially over
time as we:

•conducting clinical studies to generate evidence in support of our current and future product candidates;

•execute our marketing strategy for our current and future commercial products;

•pursue the ongoing and planned development of new products in our pipeline;

•seek to discover and develop additional product candidates;

•hire additional scientific and research and development personnel; and

• add additional operational, financial and management information systems and personnel.


Furthermore, we expect to continue to incur additional costs associated with
operating as a public company, including significant legal, accounting, investor
relations and other expenses.

Impact of the COVID-19 pandemic


We are continuing to closely monitor the impact of the ongoing COVID-19 pandemic
on our business and taking proactive efforts designed to protect the health and
safety of our workforce, continue our business operations and advance our
corporate objectives. We are providing the following update with respect to the
impact of COVID-19 on our business:

•We have maintained and expect to continue to maintain uninterrupted business
operations, with adequate access to reagents and consumables needed for testing
patient samples and normal turnaround times for our delivery of test reports. We
have continued to maintain our previously implemented adjustments to our
operations designed to keep employees safe and comply with federal, state and
local guidelines, including those regarding social distancing.

•Following the onset of the COVID-19 pandemic, we experienced declines in orders
and test report volume in certain periods. For example, in the second quarter of
2020, test reports delivered for our lead product, DecisionDx-Melanoma,
decreased 18.5% compared to the second quarter of 2019. We believe these
decreases in our test report volume were linked to delays and/or cancellations
in patient visits, resulting in fewer diagnostic biopsies and thus a reduction
in the number of diagnoses of cutaneous melanoma in response, as well as the
cumulative impact on promotional responsiveness as a result of reduced sales
calls per day and in-person sales calls during the ongoing COVID-19 pandemic.

•Our commercial team uses a combination of in-person, virtual and non-personal
promotional and educational efforts. Since the beginning of 2021, we have seen
improvements in the number of promotional calls per day, as well as a continued
shift from virtual to in-person sales calls. During the three months ended March
31, 2022 and 2021, in-person sales calls accounted for over 95% and 75% of all
calls during such periods, respectively. However, we have not yet achieved
pre-COVID-19 levels of calls per day per sales representative.

•Our future results will be dependent upon the extent and duration of the
COVID-19 crisis, including the emergence and spread of variants of the virus,
and government restrictions, which are beyond our control. Although state and
local government restrictions put in place to slow the spread of the virus have
been eased in certain locations, restrictions may be reinstated from time to
time in various regions depending on the circumstances, potentially impacting
the flow of future patient visits as well as access to our sales targets. Even
with the easing of state and local restrictions and the availability of
vaccinations, patient visits and diagnoses of the diseases covered by our
diagnostic and prognostic test may be impacted by continued apprehension
regarding possible exposure to the virus as well as a general shift from
in-person clinical visits to telehealth approaches, which may result in missed
or delayed diagnoses of skin cancer and other diseases.

                                       20

————————————————– ——————————

Contents


As conditions are continuously evolving, we are unable to predict how our future
test report volume will be impacted, or the extent to which our results of
operations, financial condition or cash flows will be impacted, by the ongoing
COVID-19 pandemic or other future public health crises. Accordingly, the test
report data presented above is not necessarily indicative of our results of
operations that can be expected for future periods. For more information on the
potential impact of the ongoing COVID-19 pandemic on our business, see the risk
factors included under "Risks Related to Our Business" and the other risk
factors included in Part II, Item 1A., "Risk Factors" in this Quarterly Report
on Form 10-Q.

Factors affecting our performance

We believe that several important factors have had and which we believe will continue to have an impact on our operating performance and results of operations, including:


•Report volume. We believe that the number of reports we deliver to physicians
is an important indicator of the growth of adoption among the healthcare
provider community. Our revenue and costs are affected by the volume of testing
and mix of customers. Our performance depends on our ability to retain and
broaden adoption with existing prescribing physicians, as well as attract new
physicians. In the near term, our report volume may be negatively impacted by
ongoing developments of the ongoing COVID-19 pandemic, as discussed above.

•Reimbursement. We believe that expanding reimbursement is an important
indicator of the value of our products. Payors require extensive evidence of
clinical utility, clinical validity, patient outcomes and health economic
benefits in order to provide reimbursement for diagnostic and prognostic
products. Our revenue depends on our ability to demonstrate the value of our
products to these payors.

•Gross margin. We believe that our gross margin is an important indicator of the
operating performance of our business. Higher gross margins reflect the average
selling price of our tests, as well as the operating efficiency of our
laboratory operations.

•New product development. A significant aspect of our business is our investment
in research and development activities, including activities related to the
development of new products. In addition to the development of new product
candidates, we believe these studies are critical to gaining physician adoption
of new products and driving favorable coverage decisions by payors for such
products.

Information on certain measures

The following provides additional information about certain measures we have disclosed in this MD&A and Analysis of Financial Condition and Results of Operations.


Test reports delivered for DecisionDx-Melanoma, DecisionDx-SCC, myPath
Melanoma/DecisionDx DiffDx-Melanoma, DecisionDx-UM and the TissueCypher
Barrett's Esophagus test represents the number of completed test reports
delivered by us during the reporting period indicated. The period in which a
test report is delivered does not necessarily correspond with the period the
related revenue, if any, is recognized, due to the timing and amount of
adjustments for variable consideration under ASC 606. We use this metric to
evaluate the growth in adoption of our tests and to measure against our internal
performance objectives. We believe this metric is useful to investors in
evaluating the volume of our business activity from period-to-period that may
not be discernible from our reported revenues under ASC 606. We also sometimes
present, on a limited basis, data on the number of orders received. We believe
order data can provide additional insight on current demand trends, particularly
during the ongoing COVID-19 pandemic and with respect to new product launches,
when considered in conjunction with test report volume. However, orders received
in a particular period do not necessarily correspond with actual delivered test
reports or reported revenues for the same period or subsequent periods.

New ordering clinicians for our dermatologic tests represents the number of
clinicians who ordered a dermatologic test from us for the first time during the
reporting period specified. Our dermatologic tests consist of
DecisionDx-Melanoma, DecisionDx-SCC and our CDO. We believe this metric is
useful in evaluating the effectiveness of our sales and marketing efforts in
establishing new relationships with clinicians and increasing the adoption of
our suite of dermatologic tests. We also believe this metric provides useful
information to investors in assessing our ability to expand the use of our
dermatologic tests. Since this metric is based upon the reporting period in
which an order is placed, it does not necessarily correspond to the reporting
period in which either a test report was delivered or revenue was recognized.

Components of operating results

Net income


We generate revenues from the sale of our products. Currently, our revenues are
primarily derived from the sale of DecisionDx-Melanoma and DecisionDx-UM. We
bill third-party payors and patients for the tests we perform.

                                       21

————————————————– ——————————

Contents


Under ASC 606, we recognize revenue at the amount we expect to be entitled,
subject to a constraint for variable consideration, in the period in which our
tests are delivered to the treating physicians. We have determined that our
contracts contain variable consideration under ASC 606 because the amounts paid
by third-party payors may be paid at less than our standard rates or not paid at
all, with such differences considered implicit price concessions. Variable
consideration is recognized only to the extent it is probable that a significant
reversal of revenue will not occur in future periods when the uncertainties are
resolved. Variable consideration is evaluated each reporting period and
adjustments are recorded as increases or decreases in revenues. Variable
consideration for Medicare claims that are not covered by an LCD or otherwise,
including those claims undergoing appeal, is deemed to be fully constrained due
to factors outside our influence (i.e., judgment or actions of third parties)
and the uncertainty of the amount to be received is not expected to be resolved
for a long period of time. For these fully constrained claims, we generally
recognize revenue in the period the uncertainty is favorably resolved, if at
all. Due to potential future changes in Medicare coverage policies and appeal
cycles, insurance coverage policies, contractual rates and other trends in the
reimbursement of our tests, our revenues may fluctuate significantly from period
to period. Additionally, our ability to recognize revenue for our recently
launched tests, DecisionDx-SCC and DecisionDx DiffDx-Melanoma, is dependent on
the development of reimbursement experience and coverage decisions for these
tests. Due to limited reimbursement experience, we are currently recognizing
revenues for these two tests on the basis of actual cash collections.

Our ability to increase our revenues will depend on our ability to further
penetrate our target markets, and, in particular, generate sales through our
direct sales force, develop and commercialize additional tests, obtain
reimbursement from additional third-party payors and increase our reimbursement
rate for tests performed.

Cost of sales (excluding amortization of intangible assets acquired)


The components of our cost of sales are material and service costs associated
with testing samples, personnel costs (including salaries, bonuses, benefits and
stock-based compensation expense), electronic medical record set up costs, order
and delivery systems, shipping charges to transport samples, third-party test
fees, and allocated overhead including rent, information technology costs,
equipment and facilities depreciation and utilities. Costs associated with
testing samples are recorded when the test is processed regardless of whether
and when revenues are recognized with respect to that test. As a result, our
cost of sales as a percentage of revenues may vary significantly from period to
period because we do not recognize all revenues in the period in which the
associated costs are incurred. We expect cost of sales in absolute dollars to
increase as the number of tests we perform increases. Additionally, we expect
cost of sales to increase with the expansion of laboratory capacity and staffing
in advance of the anticipated growth of our recently launched tests.

Gross margin and gross margin percentage are key indicators we use to assess our
business. See the table in "Results of Operations-Comparison of the three months
ended March 31, 2022 and 2021" for details.

Research and development


Research and development expenses include costs incurred to develop our
diagnostic and prognostic tests, collect clinical samples and conduct clinical
studies to develop and support our products. These costs consist of personnel
costs (including salaries, bonuses, benefits and stock-based compensation
expense), prototype materials, laboratory supplies, consulting costs, regulatory
costs, electronic medical records set up costs, costs associated with setting up
and conducting clinical studies and allocated overhead, including rent,
information technology, equipment depreciation and utilities. We expense all
research and development costs in the periods in which they are incurred. We
expect our research and development expenses to increase in absolute dollars as
we continue to invest in research and development activities related to
developing enhanced and new products.

We expect to use a portion of our cash and cash equivalents to further support
and accelerate our research and development activities, including three
important studies that are underway to support our DecisionDx-Melanoma test. The
first is the PERSONALize study, in which we are evaluating DecisionDx-Melanoma
for interactions with adjuvant therapies. The second is the CONNECTION study,
which is collecting long-term outcomes for up to 10,000 patients who have been
tested with DecisionDx-Melanoma. The third is the DECIDE study, which is
designed to determine the association of GEP test results with SLNB surgical
decisions in patients eligible for SLNB as well as to track outcomes for
patients who did and did not undergo SLNB. Also, as noted above, in 2021, we
initiated our 4,800 patient, prospective, multi-center clinical study to
develop, validate and bring to market a pipeline test aimed at predicting
response to systemic therapy in patients with moderate to severe psoriasis,
atopic dermatitis and related inflammatory skin conditions. We have also
initiated two additional disease studies for pipeline tests for new indications.

Selling, general and administrative expenses


Selling, general and administrative ("SG&A") expenses include executive, selling
and marketing, legal, finance and accounting, human resources, billing and
client services. These expenses consist of personnel costs (including salaries,
bonuses, benefits and stock-based compensation expense), direct marketing
expenses, audit and legal expenses, consulting costs, training and medical
education activities, payor outreach programs and allocated overhead, including
rent, information technology,

                                       22

————————————————– ——————————

Contents


equipment depreciation, and utilities. We expect continued increases in SG&A
expenses related to compliance with the rules and regulations of the SEC and The
Nasdaq Stock market LLC ("Nasdaq") (in particular as we have become a large
accelerated filer), investor relations activities and additional insurance
expenses. Other administrative and professional services expenses within SG&A
are expected to increase with the scale of our business, but selling and
marketing-related expenses are expected to increase significantly, consistent
with our growth strategy.

Amortization of acquired intangible assets

The amortization of acquired intangible assets is mainly associated with the technology developed.

Change in fair value of contingent consideration

The change in fair value of the contingent consideration is associated with our acquisition of Cernostic and the related additional consideration of up to
$50.0 million that may become payable depending on the achievement of certain commercial milestones relating to the financial year ended December 31, 2022 (the “Top-Up Payments”).

interest income

Interest income consists primarily of income on cash and cash equivalents, primarily money market funds.

Interest charges

Interest expense is mainly attributable to a finance lease.

income tax expense


Our consolidated financial statements do not reflect any federal or state income
tax benefits attributable to the net losses we have incurred, due to the
uncertainty of realizing a benefit from those items. As of December 31, 2021, we
had federal net operating loss carryforwards of $99.4 million, of which $43.5
million will begin to expire in 2030 if not utilized to offset federal taxable
income, and $55.9 million may be carried forward indefinitely. Also, as of
December 31, 2021, we had state net operating loss carryforwards of $67.5
million, which begin to expire in 2028 if not utilized to offset state taxable
income.

Results of Operations

Certain prior year amounts in the tables below have been reclassified to conform
to the current year presentation. Specifically, we no longer present gross
margin on the face of our financial statements and therefore the cost of sales
line is now presented within the operating expenses section. This
reclassification had no impact on operating loss, loss before income taxes or
net loss. The calculation of our gross margin is instead presented in a separate
table in following section.

                                       23

————————————————– ——————————

Contents

Comparison of the three months ended March 31, 2022 and 2021

The following table summarizes our results of operations for the periods indicated (in thousands, except percentages):

                                                         Three Months Ended
                                                             March 31,
                                                      2022                2021                         Change
                                                            (unaudited)
Net revenues                                      $   26,852          $  22,813          $   4,039                  17.7  %
Operating expenses
Cost of sales (exclusive of amortization of
acquired intangible assets)                            5,944              3,028              2,916                  96.3  %
Research and development                              10,761              5,908              4,853                  82.1  %
Selling, general and administrative                   30,453             18,161             12,292                  67.7  %
Amortization of acquired intangible assets             1,648                  -              1,648                       NA
Change in fair value of contingent consideration       2,562                  -              2,562                       NA

Total operating expenses                              51,368             27,097             24,271                  89.6  %
Operating loss                                       (24,516)            (4,284)           (20,232)               (472.3) %
Interest income                                           30                  4                 26                       NM
Interest expense                                          (3)                 -                 (3)                      NA

Loss before income taxes                             (24,489)            (4,280)           (20,209)               (472.2) %
Income tax expense                                       134                  -                134                       NA
Net loss                                          $  (24,623)         $  (4,280)         $ (20,343)               (475.3) %




NA = Not applicable

NM = Not meaningful

The following table provides a disaggregation of net revenues by type (in
thousands):

                         Three Months Ended
                             March 31,
                         2022           2021        Change
                            (unaudited)
Dermatologic(1)      $   24,339      $ 20,910      $ 3,429
Other(2)                  2,513         1,903          610
Total net revenues   $   26,852      $ 22,813      $ 4,039



(1)Includes DecisionDx-Melanoma, DecisionDx-SCC and CDO. (2) Mainly consists of DecisionDx-UM.


The following table presents the calculation of gross margin (in thousands,
except percentages):

                                                               Three Months Ended
                                                                   March 31,
                                                            2022                2021               Change
                                                                  (unaudited)
Net revenues                                           $    26,852          $   22,813          $    4,039
Less: Cost of sales (exclusive of amortization of
acquired intangible assets)                                  5,944               3,028               2,916
Less: Amortization of acquired intangible assets             1,648                   -               1,648
Gross margin                                           $    19,260          $   19,785          $     (525)
Gross margin percentage                                       71.7  %             86.7  %            (15.0) %


                                       24

————————————————– ——————————

Contents

The following table shows the amount of stock-based compensation expense (non-cash) reflected in the above line items (in thousands):

                                                             Three Months Ended
                                                                 March 31,
                                                          2022                  2021               Change
                                                                (unaudited)
Cost of sales (exclusive of amortization of
acquired intangible assets)                        $        853             $      510          $      343
Research and development                                  1,828                  1,058                 770
Selling, general and administrative                       5,738                  3,345               2,393
Total stock-based compensation expense             $      8,419             $    4,913          $    3,506



Net Revenues

Net revenues for the three months ended March 31, 2022 increased by $4.0
million, or 17.7%, to $26.9 million compared to the three months ended March 31,
2021, primarily due to $3.4 million higher revenue from dermatologic tests,
primarily DecisionDx-Melanoma, and to a lesser extent, higher revenues from our
other tests (non-dermatologic) of $0.6 million. The increase in dermatologic
revenue was primarily attributable to a 69% increase in test volumes, with
higher test reports delivered across each of our dermatologic offerings, due to
a combination of increased patient flow attributable to the easing of COVID-19
restrictions and the effects of our dermatologic sales force expansion during
the first half of 2021. The higher volumes were partially offset by the effect
of lower positive revenue adjustments related to tests delivered in previous
periods, associated with changes in estimated variable consideration, which were
$0.6 million for the three months ended March 31, 2022 compared to $5.3 million
for the three months ended March 31, 2021. The year-over-year decrease is
primarily attributable to the effect of favorable adjustments related to the
settlement and collection during the three months ended March 31, 2021 of
certain groups of receivables from prior years that did not recur during the
three months ended March 31, 2022. The increase in revenue from our other tests
(non-dermatologic) of $0.6 million was primarily attributable to higher volume
of DecisionDx-UM, which we believe is largely attributable to the easing of
COVID-19 restrictions.

Cost of sales (excluding amortization of intangible assets acquired)


Cost of sales (exclusive of amortization of acquired intangible assets) for the
three months ended March 31, 2022 increased by $2.9 million, or 96.3%, compared
to the three months ended March 31, 2021, primarily due to higher personnel
costs, attributable to additional headcount in our laboratory testing
operations, including headcount attributable to the addition of Cernostics, as
well as increased costs of supplies and services, attributable to the higher
activity levels. Due to the nature of our business, a significant portion of our
cost of sales expenses represent fixed costs associated with our testing
operations. Accordingly, our cost of sales expense will not necessarily increase
or decrease commensurately with the change in net revenues from period to
period. We expect our cost of sales (exclusive of amortization of acquired
intangible assets) to continue to increase in future periods as we hire
additional laboratory personnel and related resources to support our expected
growth in volume for our dermatologic, gastrointestinal, mental health and
pipeline tests.

Gross margin


Our gross margin percentage was 71.7% for the three months ended March 31, 2022,
compared to 86.7% for the same period in 2021. The decrease was primarily due to
this year's amortization expense associated with our acquired intangible assets,
lower positive revenue adjustments related to tests delivered in previous
periods and additional investments in laboratory headcount. In the near term, we
expect that our gross margin percentage will decline, compared to prior periods,
as we invest in additional laboratory personnel and related resources to support
the anticipated growth in our report volumes for tests in advance of obtaining
reimbursement coverage. Additionally, our gross margin percentage will continue
to be negatively impacted by amortization of intangible assets associated with
recent acquisitions.

Research and Development

Research and development expenses increased by $4.9 million, or 82.1%, for the
three months ended March 31, 2022, compared to the three months ended March 31,
2021. Approximately 51% of the increase is attributable to higher personnel
costs, primarily due to expansions in headcount in support of our growth,
including higher stock-based compensation expense of $0.8 million, and
approximately 20% is attributable to higher costs for clinical studies,
including costs related to the PERSONALize, CONNECTION and DECIDE studies. The
remainder of the increase is primarily associated with meeting costs and travel
expenses. We expect to continue to increase our research and development
expenses as we fund ongoing evidence development for our existing products as
well as additional pipeline programs.

                                       25

————————————————– ——————————

Contents

Selling, general and administrative expenses

The following table provides a breakdown of SG&A expenses (in thousands):

                                                          Three Months Ended
                                                              March 31,
                                                          2022           2021         Change
                                                             (unaudited)
Sales and marketing                                   $   18,221      $  9,656      $  8,565
General and administrative                                12,232         

8,505 3,727 Total selling, general and administrative expenses $30,453 $18,161 $12,292



Sales and marketing expenses increased by $8.6 million, or 88.7%, for the three
months ended March 31, 2022, compared to three months ended March 31, 2021.
Approximately $5.4 million, or 63%, of the increase is attributable to higher
personnel costs including salaries, bonuses and stock-based compensation.
Stock-based compensation expense included in sales and marketing expense was
$2.8 million for the three months ended March 31, 2022, compared to $1.5 million
for the three months ended March 31, 2021. Personnel costs have increased
through the expansion of our dermatology-facing commercial team headcount to the
mid-60s during the first and second quarters of 2021 and through our acquisition
of Cernostics in December 2021, where we hired an initial commercial team of
approximately 14 outside sales territories, along with commensurate internal
sales associates and other personnel, to support our launch of the TissueCypher
Barrett's Esophagus test and to serve as a dedicated team focused on
gastroenterology specialists that diagnose and manage patients with BE. The
remainder of the increase in sales and marketing expenses was primarily
associated with training events, meetings, travel and other general increases.
The higher expenses for training events and travel reflect both a higher
headcount as well a return to more in-person activities resulting from the
continued easing of COVID-19 restrictions. We expect sales and marketing
expenses to increase in future periods as we intend to expand our outside sales
territories and sales force further during 2022, as discussed under "Overview"
above.

General and administrative expenses increased by $3.7 million, or 43.8%, for the
three months ended March 31, 2022, compared to three months ended March 31,
2021. The increase is primarily attributable to $2.6 million in higher personnel
costs including salaries, bonuses and stock-based compensation. Stock-based
compensation expense included in general and administrative expense was $2.6
million for the three months ended March 31, 2022, compared to $1.4 million for
the three months ended March 31, 2021. The higher personnel costs reflect
expanded headcount in our administrative support functions. The remainder of the
increase in general and administrative expenses was primarily associated with
professional fees and other general increases.

Amortization of acquired intangible assets


Amortization of acquired intangible assets was $1.6 million for the three months
ended March 31, 2022 and was primarily associated with amortization of developed
technology attributable to the acquisitions of Myriad myPath, LLC and Cernostics
in May 2021 and December 2021, respectively. There was no such amortization
during the three months ended March 31, 2021.

Change in fair value of contingent consideration


The change in fair value of contingent consideration for the three months ended
March 31, 2022 of $2.6 million is related to the remeasurement of the Earnout
Payments associated with our acquisition of Cernostics and primarily reflects
the passage of time. There was no such activity during the three months ended
March 31, 2021.

Stock-based compensation expense


Stock-based compensation expense, which is allocated among cost of sales,
research and development expense and SG&A expense, totaled $8.4 million for the
three months ended March 31, 2022, compared to $4.9 million for the three months
ended March 31, 2021. We expect material increases in stock-based compensation
expense in future periods, reflecting mainly higher awards outstanding due to
growth in our headcount. As of March 31, 2022, we had 400 employees compared to
242 as of March 31, 2021. As of March 31, 2022, the total unrecognized
stock-based compensation cost related to outstanding awards was $97.1 million,
which is expected to be recognized on a straight-line basis over a
weighted-average period of 3.1 years. We expect to continue granting stock-based
compensation awards, which we expect to further contribute to increases in
stock-based compensation expense in future periods.

                                       26

————————————————– ——————————

Contents

Cash and capital resources

Sources of liquidity


Our principal sources of liquidity are our cash and cash equivalents and cash
generated from the sale of our products. As of March 31, 2022 and December 31,
2021, we had cash and cash equivalents of $309.0 million and $329.6 million,
respectively. In addition to the revenue generated from the sale of our
commercial products, we have financed our operations through our IPO in July
2019, two follow-on public offerings of common stock in June 2020 and December
2020, and a $25.0 million secured term loan credit facility, which we repaid in
full in December 2020.

On December 14, 2020, we filed an automatically effective shelf registration
statement on Form S-3 (File No. 333-251331) (our "Shelf Registration Statement")
with the SEC as a "well-known seasoned issuer." The Shelf Registration Statement
allows us to issue an indeterminate number or amount of common stock, preferred
stock, debt securities and warrants from time to time in one or more offerings.
However, there can be no assurance that we will complete any further offerings
of securities under our Shelf Registration Statement. Any future offerings under
our Shelf Registration Statement will be dependent upon, among other factors,
market conditions, available pricing, our financial condition, investor
perception of our prospects, our capital needs and our ability to maintain
status as a well-known seasoned issuer. Our market capitalization as of May 6,
2022 is below the level required to maintain status as well-known seasoned
issuer in the future.

As mentioned above, we expect to use a portion of our cash and cash equivalents,
including any proceeds from subsequent offerings under our Shelf Registration
Statement, to further support and accelerate our research and development
activities, including the clinical studies noted above in "Components of the
Results of Operations-Research and Development."

Material cash needs


Our primary uses of capital are, and we expect will continue to be, compensation
and related expenses, clinical research and development services, laboratory
operations, equipment and related supplies, legal and other regulatory expenses,
general administrative costs and, from time to time, expansion of our laboratory
and office facilities in support of our growth. We anticipate that a substantial
portion of our cash requirements in the foreseeable future will relate to the
further commercialization of our currently marketed products, the development of
our future product candidates in our pipeline and the potential
commercialization of these pipeline products, should their development be
successful.

In December 2021, we acquired Cernostics for $30.7 million in cash and in April
2022, we acquired AltheaDx, for $32.5 million in cash and $32.5 million in
shares of our common stock. Under the definitive agreement to acquire
Cernostics, we also agreed to pay up to an additional $50.0 million of Earnout
Payments, based on the achievement of certain commercial milestones relating to
the year ending December 31, 2022. With respect to AltheaDx, we agreed to pay up
to an additional $75.0 million, 50% in cash and 50% in common stock, based on
the achievement of certain commercial milestones relating to the years ending
December 31, 2022, 2023 and 2024. Our actual liability with respect to these
commercial milestone payments from our acquisitions will depend, in part, on our
ability to successfully integrate the TissueCypher Barrett's Esophagus test
(acquired from Cernostics) and IDgenetix (acquired from AltheaDx) into our suite
of commercial product offerings.

Since our inception, we have generally incurred significant losses and negative
cash flows. For the year ended December 31, 2021 we had a net loss of $31.3
million and an accumulated deficit of $93.8 million as of December 31, 2021. For
the three months ended March 31, 2022, we had a net loss of $24.6 million and an
accumulated deficit of $118.4 million as of March 31, 2022. Our ability to
generate revenue sufficient to achieve profitability will depend heavily on the
successful commercialization of our currently marketed products and the products
we plan to launch in the future as well as our spending on research and
development activities. We expect to incur additional expenses and losses in the
future as we invest in the commercialization of our existing products, the
development of our future product candidates and the commercialization of our
product candidates. Further, we expect that any acquisitions of businesses,
products, assets or technologies will also increase our expenses. We believe
that our existing cash and cash equivalents and anticipated cash generated from
the sale of our commercial products will be sufficient to fund our operations
for the next twelve months. We believe we will meet longer-term expected cash
requirements and obligations through a combination of existing cash and cash
equivalents, anticipated cash generated from sales of our products and issuances
of equity securities or debt offerings, including through our Shelf Registration
Statement. However, we have based these estimates on assumptions that may prove
to be wrong, and we could utilize our available capital resources sooner than we
expect. There are numerous risks and uncertainties associated with developing
genomic tests, including, among others, the uncertainty of:

• successful initiation and completion of clinical study protocols;

•successful identification and acquisition of tissue samples;

•the development and validation of genomic classifiers; and

•the acceptance of new genomic tests by doctors, patients and third-party payers.

                                       27

————————————————– ——————————

Contents


Because of the numerous risks and uncertainties associated with research,
development and commercialization of product candidates, we are unable to
estimate our exact working capital requirements. Our future funding requirements
will depend on and could increase significantly as a result of many factors,
including those listed above as well as those listed in Part II, Item 1A., "Risk
Factors" in this Quarterly Report on Form 10-Q.

We do not currently have any committed external source of funds. In the event
additional funding is required, we expect that we would use a combination of
equity and debt financings, which may not be available to us when needed, on
terms that we deem to be favorable or at all. To the extent that we raise
additional capital through the sale of equity or convertible debt securities,
the ownership interest of our stockholders will be diluted, and the terms of
these securities may include liquidation or other preferences that adversely
affect the rights of common stockholders. Debt financing and preferred equity
financing, if available, may involve agreements that include covenants limiting
or restricting our ability to take specific actions, such as incurring
additional debt, making acquisitions or capital expenditures or declaring
dividends. Any disruptions to, or volatility in, the credit and financial
markets or any deterioration in overall economic conditions may make any
necessary debt or equity financing more difficult to obtain, more costly and/or
more dilutive. If we are unable to raise additional funds through debt or equity
financings or other arrangements when needed, we may be required to delay,
limit, reduce or terminate our product discovery and development activities or
future commercialization efforts.

Leases


We have entered into various operating and finance leases, which are primarily
associated with our laboratory facilities and office space. Total undiscounted
future minimum payment obligations under our operating leases and finance leases
as of March 31, 2022 totaled approximately $10.3 million, of which $1.0 million
is payable through the remainder of 2022 and $9.3 million through the end of
2033. The leases expire on various dates through 2033 and provide certain
options to renew for additional periods. On March 11, 2022, we amended an
existing lease agreement to lease additional laboratory space in Phoenix,
Arizona. On April 1, 2022, we entered into a new lease agreement with an initial
term of 10.5 years for laboratory and office space located in Pittsburgh,
Pennsylvania. As of March 31, 2022, neither of the two leases had commenced.
Upon commencement, we expect these two leases to increase our undiscounted
future minimum payment obligations by a total of approximately $13.8 million.

Cash flow

The following table summarizes our sources and uses of cash and cash equivalents for each of the periods presented (in thousands):

                                                           Three Months Ended
                                                               March 31,
                                                                         2022           2021
                                                                             (unaudited)
Net cash used in operating activities                                 $ (21,430)     $  (3,631)
Net cash used in investing activities                                      (402)          (750)
Net cash provided by financing activities                                 1,216          1,510
Net change in cash and cash equivalents                                 (20,616)        (2,871)
Cash and cash equivalents, beginning of period                          329,633        409,852
Cash and cash equivalents, end of period                              $ 309,017      $ 406,981


Operating Activities

Net cash used in operating activities was $21.4 million for the three months
ended March 31, 2022, and was primarily attributable to the net loss of $24.6
million, decreases in accrued compensation of $6.9 million and increases in
accounts receivable of $2.7 million, partially offset by non-cash stock
compensation expense of $8.4 million, change in fair value of contingent
consideration of $2.6 million and depreciation and amortization of $2.2 million.

Net cash used in operating activities was $3.6 million for the three months
ended March 31, 2021, and was primarily attributable to the net loss of $4.3
million, decreases in accrued compensation of $3.9 million, increases in
accounts receivable of $1.6 million and decreases in other accrued liabilities
of $0.3 million, partially offset by stock compensation expense of $4.9 million
and decreases in prepayments and other current assets of $1.7 million.

The $17.8 million additional net cash used in operating activities for the three
months ended March 31, 2022 compared to the three months ended March 31, 2021 is
primarily due to cash requirements associated with the increases in operating
expenses, the majority of which were attributable to salaries, bonuses and
benefits due to our growth in headcount, as discussed in further

                                       28

————————————————– ——————————

Contents


detail under "Results of Operations-Comparison of the three months ended March
31, 2022 and 2021" above. The effect of the higher expenses on net cash used in
operating activities was partially offset by the higher revenues.

Investing activities

Net cash used in investing activities for the three months ended March 31, 2022
and 2021 consisted of purchases of property, plant and equipment in both periods.

Fundraising activities


Net cash provided by financing activities was $1.2 million for the three months
ended March 31, 2022, and primarily consisted of $0.9 million in proceeds from
contributions to the employee stock purchase plan and $0.4 million in proceeds
from the exercise of stock options.

Net cash provided by financing activities was $1.5 million for the three months
ended March 31, 2021, and primarily consisted of $1.0 million in proceeds from
the exercise of stock options and $0.9 million in proceeds from contributions to
the employee stock purchase plan.

Critical accounting estimates


During the three months ended March 31, 2022, there were no significant changes
to the information discussed under "Critical Accounting Estimates" included in
the Management's Discussion and Analysis of Financial Condition and Results of
Operations section of our Annual Report on Form 10-K for the year ended December
31, 2021.

© Edgar Online, source Previews


Source link

]]>